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ABSTRACT 
 
Microcrystals promote cystogenesis and exacerbate autosomal dominant polycystic kidney 
disease 
 
by 
 
Jacob Alexander Torres 
 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder 
affecting approximately 2.5 million people worldwide. It is the number one, life-threatening 
monogenic disorder known, caused by mutations in either the Pkd1 or Pkd2 genes resulting 
in numerous fluid-filled cysts within the kidneys. ADPKD presents in the 2nd decade of life 
and presents with progressive renal decline and eventually to end stage renal disease (ESRD) 
in the 5th to 6th decade of life for half of all patients. Currently no treatments exist to 
ameliorate or cure ADPKD, creating a large financial burden on both the health care system, 
the patient, and their care-givers1. Treatment options once patients reach ESRD are limited 
to dialysis and kidney transplant. Since the discovery of the genetic link to ADPKD, there 
has been intense research to understand what role the Pkd1/2 genes play in the formation of 
cysts and the progression of ADPKD. The slow progression of ADPKD and the difference in 
disease severity between individuals implies that there may be environmental factors acting 
as causative agents in promoting cyst formation2. Animal models of ADPKD appear to be 
more susceptible to cyst formation following injury with nephrotoxic chemicals, ischemia, 
and partial or total unilateral nephrectomy3–5. These data demonstrate that the injured state is 
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a driver of cyst formation once Pkd1/2 have been mutated, but these experimental 
approaches are not representative of normal environmental injuries to the kidney. The focus 
of my research is to elucidate an environmental agent that can promote cystogenesis in an 
otherwise healthy individual. The kidney is responsible for filtering solutes from the blood 
which include ions and molecules that under the right circumstances can form precipitates in 
the urinary filtrate. It is our hypothesis that the endogenous kidney injury in ADPKD patients 
results via the precipitation of microcrystals and the inappropriate response to crystal 
clearance. The kidney is producing sub-clinical microcrystals daily that are excreted into the 
urine without incident. Individuals with ADPKD may be unable to respond appropriately in 
the clearance of these small crystals. Previously, our lab has shown that ADPKD cyst lining 
epithelial cells exhibit increased levels of mTOR and STAT3 activity6–8. This same 
activation of mTOR and STAT3 can be seen following calcium oxalate crystal deposition in 
both wild-type mice and rats. In addition to the increase in STAT3 and mTOR activity, there 
is a concomitant increase in tubule dilation. This dilation persists until crystals are no longer 
detected in kidneys along with a cessation of mTOR and STAT3 activity. Additionally, we 
demonstrate that the Han:SPRD and pck rat models of PKD exhibit an exacerbated renal 
phenotype following an increase in kidney microcrystals. Cyst number and cystic index 
increase following crystal deposition demonstrating that the mechanism of cystogenesis is 
crystal dependent. The discovery that crystals act as a trigger for cyst formation is an 
important step in elucidating the causal mechanism of cystogenesis in ADPKD and a critical 
step in creating effective preventative and palliative strategies.  
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I. Introduction 
Autosomal Dominant Polycystic Kidney Disease 
Autosomal dominant polycystic kidney disease (ADPKD) is a slow-onset disease, 
characterized by the generation of multiple fluid filled cysts within the kidney. Presenting in 
early adulthood, ADPKD is manageable until the 4th or 5th decade of life when cystic and 
fibrotic tissue replace normal, healthy tissue leading to renal failure9. ADPKD is a 
monogenic disorder caused by mutations in either the Pkd1 or Pkd2 alleles and their 
respective gene products polycystin-1 or polycystin-2 respectively. Mutations in Pkd1 
account for approximately 85% of cases reported with Pkd2 mutations comprise the 
remaining 15% of cases10. ADPKD has an extremely high penetrance, and can be caused 
sporadically affecting between 1:400 and 1:1000 live births world-wide making it the 
number one life-threatening monogenic disorder.  
In addition to the effects of ADPKD on the individual, the societal cost of ADPKD is 
extremely high due to lost wages and governmental aid for treatment1. Research on targeting 
molecular pathways associated with ADPKD has yielded little return on investment leaving 
dialysis and kidney transplantation as the only viable alternatives after the onset of end stage 
renal disease (ESRD). In 2010, 32.9 million Americans began dialysis because of cystic 
kidney disease. Among the ADPKD patients receiving dialysis, 10% developed ESRD. The 
annual expenditure for dialysis in the United States currently exceeds $47 billion making 
alternative treatments fiscally important. The lack of ADPKD treatment options and the cost 
of dialysis creates an enormous societal cost from the lost earning potential of sufferers 
along with the loss of tax payer dollars to support healthcare costs for patients1,11. Depending 
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on disease severity, annual spending for advanced stage patients can reach between 
approximately $30,000-$140,000 for care including dialysis and medication11.  
Focus on the treatment of ADPKD is to preserve renal function for as long possible. 
Individuals with ADPKD living in the United Kingdom have recently been able to receive 
the only clinically approved therapy, Tolvaptan. Tolvaptan is a vasopressin antagonist that 
may help to reduce the progression of ADPKD by decreasing the levels of cyclic-AMP 
within cysts12. Tolvaptan has been used previously for the treatment of hyponatremia and has 
recently been approved for the treatment of ADPKD. The side effects of increased and 
frequent urination from Tolvaptan make it difficult for patients to tolerate and there are 
dangerous contraindications with other drugs, making it far from a treatment of choice or a 
cure for ADPKD. 
The function of the polycystin-1 and polycystin-2 proteins is still poorly understood in 
ADPKD. Polycystin-1 associates with TSC2, an important regulator of the mTOR pathway. 
Together, the polycystin-1 and polycystin-2 proteins cooperate to form a calcium channel  
found on the primary cilium of kidney epithelial cells, allowing luminal fluid flow sensation 
by increasing intracellular calcium permiability13. 
Homozygous mutations in Pkd1/2 or autosomal recessive PKD (ARPKD), leads to rapid 
cyst formation in utero, birth defects and premature death. The loss of heterozygosity in 
Pkd1/2 is a hallmark of the disease state and has led to the development of a “two hit” model 
of cystogenesis. Inactivation of Pkd1 prior to post-natal day 13 (P13) in mice leads to rapid 
cyst formation whereas inactivation after P13 only results in cyst formation after 5 months14. 
The slow onset of cystogenesis can be accelerated with renal injury leading to a “three hit” 
model for cyst formation2,15. This model has been tested with different kidney injuries 
including: nephrotoxins, ischemia reperfusion, and, unilateral and partial nephrectomy3–5,15.  
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Many other polycystic kidney disorders have been characterized in addition to ADPKD, 
stemming from the lack of critical polycystin like proteins16, lack of or dysregulated primary 
cilia17, or the dysregulation of planar cell polarity5. Trafficking of polycystin-1 to the 
primary cilia has also been shown to be critical for cyst formation18.The interface between 
the PKD disorders appears to be regulation of cell polarity and signaling through the primary 
cilia as many proteins known to result in PKD are associated in some way with primary cilia 
or ciliary trafficking19,20. Additionally, the loss of the primary cilia has been shown to be 
critical in the development of PKD following injury21. Loss of primary cilia maintenance 
critically disrupts cellular signaling, planar cell polarity and the localization of the 
polycystins19.   
The primary cilia associates with a host of proteins needed for control of cell signaling 
including; proliferation, differentiation, tissue maintenance, cell polarity and proper ciliary 
maintenance. Loss of any of the trafficking proteins for cilia maintenance results in alteration 
of cilia integrity or loss of the cilia entirely17. The primary cilia are involved in signaling by 
interacting with the extracellular environment and integrating signals via interacting proteins 
along the surface of cilium. The cilia act as a mechanosensor and can detect bending from 
extracellular tension. An example is fluid flow in the tubule lumen. Cilia bending has been 
shown to be able to activate PC1/2 mediated calcium channel activity that inhibits increases 
in intracellular cAMP13. Mechanical bending of the cilia has also been shown to produce 
PC1 cleavage of the C-terminal tail leading to p100 mediated gene transcription22. Loss of 
cilia produces a mislocalization of the polycystins and the inability to signal the presence of 
fluid flow.  
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Cystogenesis 
The Three Hit Hypothesis posits that cyst development is believed to be a multifactorial 
process of mutation and injury, resulting in a futile repair mechanism2. The model of cyst 
development currently accepted by the field is akin to the model for cancer development. 
The Three Hit Hypothesis predicts that Pkd1 or Pkd2 mutations alone are not sufficient to 
promote cyst formation, nor is the loss of heterozygosity23. Instead cyst formation results 
from the accumulation of both genetic and somatic mutations followed by a “third hit” injury 
to the kidney2,15. This model of cystogenesis can explain the slow-progression of cyst 
formation observed in ADPKD.  
The “hits” are a stepwise function leading to the formation of a cyst. The “first hit” is a 
germ line mutation of the Pkd1/2 allele. Kidney epithelial cells are still able to function and 
behave as normal due to the functional redundancy of the second allele of Pkd1/2. At some 
point, a “second hit” occurs to the functional copy of Pkd1/2, creating a somatic mutation 
and a cell that contains two mutated Pkd1/2 genes. Work done on elucidating the origin of 
cysts has shown that cysts result from a clonal expansion of a single mutated cell that exhibit 
unique mutations between cysts24. This shows that there was a loss of heterozygosity due to 
somatic mutation prior to cyst formation.  This loss of heterozygosity alone, however, is not 
sufficient to promote cyst formation as has been demonstrated using an inducible Pkd1 
knockout mouse line25.  Following this second hit, the kidney appears normal for many 
months, even with the complete loss of heterozygosity. This could also explain the slow 
progression of the diseases in humans.  
 In addition to the germ line and somatic mutations required for cyst formation, it has 
been shown that both the timing of the mutations and the application of the “third hit” injury 
are necessary for rapid cyst formation23. Application of an injury results in rapid cyst 
  xv 
formation following the loss of Pkd1/2 in several studies3–5,15,26,27. In animal models 
mutation of Pkd1/2 is embryonic lethal due to the role of polycystin-1/2 in organogenesis 
during development10. To circumvent the lethality of PC1/2 mutation, animal models used to 
study ADPKD utilize inducible knockouts or animals with variegated expression of PC1/2 to 
study their effects on cyst formation3,4,23. Both complete and partial inactivation of PC1 has 
been shown to play a critical role in cyst development28. Animals that have PC1 inactivated 
at embryonic day 13 (E13), show rapid cyst development in utero whereas after P28, 
analogous to a young adult human, there was no cyst formation for more than 12 weeks. If 
there was an injury to the kidney however, then cyst formation occurred rapidly23,25. The 
mouse kidney is fully developed after 1 month (P28) implicating cystogenesis is facilitated 
by mitogenic signaling in the developing animal. In support of this, PC1 has been shown to 
be a direct regulator of the mTOR signaling pathway29 and when looking at ADPKD kidneys 
in mice, we can see that there is an upregulation of Src and mTOR signaling6–8,30. These 
signaling pathways for growth and proliferation are highly expressed in the developing 
animal until maturity and may account for the lack of cyst development after the 
developmental cutoff. Following injury there is an increase in cell proliferation and the re-
activation of the mTOR and Src signaling pathways. Injury induced cyst formation is most 
likely caused by the initiation of cellular repair in response to insult and the upregulation of 
these mitogenic signaling pathways from the repair process27. Injuries that trigger 
cystogenesis have come in the form of nephrotoxic compounds4, partial and total unilateral 
nephrectomy21, and ischemia reperfusion3. Each of these injuries to the kidney creates an 
environment where the kidney must undergo a process of repair and proliferation in response 
to insult15.  
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The Three Hit model of cystogenesis hypothesizes the defect in ADPKD to be associated 
with a futile repair response following injury2. While experimental treatments have 
demonstrated that the ADPKD kidney’s response to injury is maladapted, the sources of 
experimental injury are not likely to account for the cause of human ADPKD cystogenesis. 
ADPKD is a slow onset disease, implying that the triggering third hit is an environmental 
factor. The failure of the experimental approaches thus far is that they have not been able to 
show what the endogenous trigger for injury might be. While various forms of kidney injury 
are sufficient to promote cystogenesis in the context of a Pkd1/2 null animal, none of these 
techniques point to an endogenous trigger. What that trigger may be has been elusive to this 
point, but may be a potential therapeutic target for intervention.  
My research aims to uncover an as of yet, unrecognized mechanism for the clearance of 
tubular obstruction and a form of kidney injury. I propose that tubular injury caused by the 
interaction between the tubule lumen and microcrystals act as a third hit that causes disease 
progression in PKD mutant cells. Crystal obstruction causes the cessation of fluid flow and 
the production of cellular intermediates such as reactive oxygen species and inflammatory 
cytokines. This process leads to the activation of the mTOR and STAT3 signaling pathways 
along with tubule dilatation (Fig. 1, 3B,C,E). In normal kidneys, this process stops once the 
tubule is cleared of the crystals but will continue to grow and form a cyst in a polycystic 
kidney.   
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 Figure 1: Model of microcrystal induced cystogenesis: Interaction between microcrystals 
and the tubule lumen cause the tubule to dilate in response to occlusion. Dilatation occurs 
allowing for the crystal to be flushed out. Under normal circumstances the tubule returns to 
normal diameter but in PKD kidney this effect persists, leading to a cyst. 
Cyst Structure and Function 
 Cysts are a fluid filled monolayer created from the epithelial layer of cells in the 
tubule lumen of the kidney (Fig. 1). Cysts have been shown to be created from the clonal 
expansion24 of mutant cells along any tubule segment of the nephron, with the origin of 
which depending on the model being studied. The lumen of the cysts contains a host of 
secreted factors including cytokines, secondary messengers and immunoglobins31. The 
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increase in cyst size and number leads to a hypoxic environment as the renal parenchyma is 
replaced with fibrotic tissue as cysts proliferate and expand. 
The change in kidney architecture leads to a shift in cellular metabolism towards aerobic 
glycolysis similar to the Warburg effect observed in hypoxic tumors32. Treatment with the 
glycolysis inhibitor 2-deoxyglucose, has been shown to be effective in ameliorating the size 
of cysts in rodent models32. Sans metastasis, the similarities between cysts and cancer are 
striking as both cysts and cancerous tumors are in hypoxic environments, formed by multiple 
gene mutations, exhibit an increase in mitogenic and autocrine signaling, are proliferative, 
and change their metabolism to allow for continuous growth.  
The epithelial cells lining cysts exhibit strong proliferative signals. Our lab has studied 
the effect of the mTOR pathway as a treatment for PKD, as cysts show increased levels of 
phospho-S6 in all models of PKD including human ADPKD7,8. The role of mTOR and cyst 
growth is demonstrated by inhibition of the mTOR pathway with rapamycin as an effective 
treatment in the BPK mouse and the Han:SPRD rat8,33 model of PKD. Treatment with 
rapamycin or rapalogs has been shown to slow the disease progression in animals, but  
unfortunately was ineffective in human trials and may be potentially dangerous for long-term 
application34. Cyst fluid is highly enriched in cAMP leading to the assumption that the effect 
of vasopressin antagonism may provide relief to cyst development35. Altering cAMP 
signaling with the vasopressin antagonist Tolvapton12 is modestly effective, but not without 
side effects such as polyuria and nocturia that lead to a high rate of non-compliance. Thus, it 
is important to identify additional, druggable targets to halt or slow progression of the 
disease. 
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Animal Models of PKD 
The varying ways in which PKD can manifest has produced several orthologous and 
non-orthologous animal models that are utilized to study PKD. Prior to the discovery and 
cloning of the Pkd1 gene into mouse models, several rat models had been studied for their 
sporadic PKD phenotypes. For my research, I utilized the non-orthologous 
Hannover:Sprague-Dawley and pck rats. The cystic disease from these animals results from 
mutations in the proteins samcystin and fibrocystin respectively16,36. These models of PKD 
have been well established and are widely used for the study of ADPKD.  
An extensive list of animal models has been developed to study ADPKD. These include 
mutations in Pkd1, Pkd2, cilia trafficking proteins, polycystin homologs and other genes 
involved in more rare forms of PKD and nephronophthisis10,18,18. The animals that I have 
utilized to perform my research are discussed in more detail below. 
Pck Rat  
The pck rat is a non-orthologous model of PKD that exhibits extra renal manifestations 
in the liver and form cysts in the thin ascending limb of Henle, cortical collecting ducts and 
distal tubules which make its phenotype more similar to human PKD37. The mutation 
associated with the pck rat is the polycystin like protein fibrocystin, encoded by the Pkhd1 
gene. A significant difference with the pck rat phenotype is autosomal recessiveness  rather 
than autosomal dominanance38.  This mode of inheritance and the gene product fibrocystin’s 
localization to primary cilia make the pck rat an incomplete model of ADPKD. Fibrocystin 
localizes to primary cilia and associates with the NPHP family of proteins. The NPHP 
proteins are associated with nephronophthisis, a recessive PKD disease. This association and 
the recessive inheritance make the pck rat more related to a ciliary disease model of PKD. 
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Han:SPRD  
The Hannover rat is a non-orthologous model of ADPKD that was discovered in a 
colony of Sprague Dawley rats in 198939. These animals are carried as heterozygous 
mutants, with males exhibiting a more severe cystic phenotype than females40. Homozygous 
male animals do not survive past 3 weeks of age with kidneys so large they begin to affect 
breathing and movement. Heterozygous males develop cysts rapidly until 8 weeks of age and 
then begin to lose kidney function for several months until reaching ESRD. Interestingly, 
females do not suffer from the same level of PKD as males. This difference in between the 
sexes has correlates in human ADPKD, as males are observed to suffer from more severe 
forms of the disease than do their female counterparts. This difference in the PKD phenotype 
was utilized in our research for designing experiments to assess the effects of treatments 
between male and female rats treated with ethylene glycol and their cystogenic response. It is 
worth mentioning that female rats are not susceptible to the effects of ethylene glycol 
administration unlike the male rats, which readily produce calcium oxalate crystals in 
response to ethylene glycol. 
My research has utilized both of the described animal models to study PKD.  Despite 
their limitations both have proven useful. In Chapter II, I present my results using both rat 
models of PKD to study the effects of crystal deposition and the effects of crystals on 
cystogenesis. In Chapter IV I use the Han rat to study the possibility that a ketogenic diet 
may be effective at treating ADPKD.  
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II.      
Renal Crystal Deposition Leads to Tubule Dilation to Facilitate 
Excretion in Normal Kidneys but Promotes Cystogenesis in 
Polycystic Kidney Disease 
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This chapter is in preparation for submission with the following co-authors; 
Mina Rezaei1, Louis Lin1, Caroline Broderick1, 
Benjamin Cowley2, Vicente Torres3, Saeed Khan4, Thomas Weimbs1* 
 
1University of California Santa Barbara, Department of Molecular, Cellular, 
and Developmental Biology, and Neuroscience Research Institute; 
2University of Oklahoma Health Sciences Center, Department of Medicine; 
4Mayo Clinic College of Medicine, Division of Nephrology; 
4University of Florida, Department of Pathology 
Abstract 
ADPKD is a progressive disease characterized by the accumulation of fluid-
filled cysts, slowly replacing healthy tissue progressing to renal failure.  
Individuals with ADPKD suffer from many renal pathologies including 
nephrolithiasis. Throughout evolutionary time the kidney has developed 
mechanisms to allow for small occluding bodies to be passed without incident. 
We hypothesize that tubular expansion and cyst formation is an aberrant activation 
of this endogenous pathway. Administration of sodium oxalate via intraperitoneal 
injection leads to calcium oxalate crystal deposition inside kidney tubules and 
subsequent activation of the mTOR, Src and STAT3 pathways and concomitant 
tubule expansion in wild type rats and mice.  We demonstrate crystal dependent 
cystogenesis in both the Han:SPRD and pck rat. The discovery of microcrystals as 
the endogenous trigger for cyst formation allows for an avenue of therapeutic 
intervention, potentially without the use of dangerous or unsustainable drug 
treatments.  
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A. Introduction 
ADPKD is a common, life-threatening genetic disease that causes immense 
human suffering and places a significant economic burden to the health care 
system1. Progressive renal cyst growth leads to the deterioration of normal renal 
parenchyma, and approximately 50% of patients will require dialysis or kidney 
transplantation in adulthood9. No approved treatment to slow or halt disease 
progression is available in the US. Recently, a vasopressin receptor antagonist, 
Tolvaptan, has been approved for ADPKD in other countries but the utility of this 
drug may be limited by significant adverse effects, potential liver toxicity and high 
costs41. There is an urgent need for effective and safe treatment options for 
ADPKD. 
 ADPKD is caused by mutations in either the Pkd1 or Pkd2 gene. 
Numerous functions for the respective gene products, polycystin-1 (PC1) and 
polycystin-2 (PC2), have been identified, but the actual role of the polycystins in 
the kidney remains to be determined42. The rate of disease progression in ADPKD 
exhibits high inter- and intra-familial variability, suggesting involvement of 
modifier genes and/or environmental factors43–47, yet none have been clearly 
identified. If an environmental factor influences disease progression it would be of 
utmost importance to identify it so that it can be controlled. Support for a role of 
environmental factors as determinants of disease progression in ADPKD has come 
from genetic mouse experiments that culminated in the widely accepted “third hit” 
model of cystogenesis2. In this model three events must occur to trigger the 
formation of individual cysts in ADPKD: the “first hit” is a germline mutation in 
the Pkd1 or Pkd2 gene; the “second hit” is a random somatic mutation in a single 
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tubule cell that affects the other Pkd1/Pkd2 allele; the “third hit” is an insult to the 
affected kidney such as ischemic or toxic damage that triggers a repair response. 
Indeed, elimination of both Pkd1 alleles in mature mouse kidneys alone does not 
lead to cyst growth for many months 14. However, subsequent renal injury in such 
mice – or similarly pre-conditioned mice - will trigger rapid cyst growth2–5,15,21. In 
human ADPKD, new cysts are thought to arise throughout life48. Since most 
“second hits” (somatic mutations) in ADPKD patients presumably occur long after 
kidney maturation, it is likely that subsequent “third hits” (damage/repair) are also 
required for cystogenesis in humans. However, ischemic or toxic kidney damage 
are infrequent events in humans and unlikely to explain the relatively constant 
progression of ADPKD although it is possible that subclinical levels of such 
injuries may play a role. We therefore hypothesized that a much more prevalent, 
and clinically relevant, mechanism may drive disease progression as a “third hit” 
trigger, and considered tubule occlusion or injury by sporadically lodged 
microcrystals. 
Kidneys are constantly challenged by super-saturated solutes – such as 
calcium oxalate (CaOx), calcium phosphate (CaP), uric acid and others – present 
in the urinary filtrate that may precipitate while passing through the tubular 
system. While millions of microscopic crystals may form in human kidneys daily, 
most are excreted safely with the urine49,50. Diets and numerous pathologies 
greatly influence the range of crystal burden that the kidneys experience. Up to a 
quarter of fresh urines from normal subjects exhibit overt crystalluria51 without 
immediate detriment to normal kidneys. Innate mechanisms prevent excessive 
growth and retention of crystals within the luminal space. Otherwise, tubules 
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would rapidly become occluded and renal function would seize. Protective 
mechanisms include renal regulators of crystal nucleation and growth such as 
osteopontin, nephrocalcin and Tamm-Horsfall Protein (THP)50. If crystals do 
become lodged in renal tubules, e.g. due to fast growth or aggregation, it can lead 
to nephrolithiasis. The fate of such lodged microcrystals is poorly understood but 
the main proposed mechanism for their excretion is that they cross the epithelium 
into the interstitial space where they would either be resorbed or lead to the 
formation of kidney stones52. In humans, 70-80% of all kidney stones are 
composed of CaOx indicating that oxalate provides a particular challenge.  
Several correlative observations may support a link between ADPKD 
progression and renal crystal burden. Symptomatic nephrolithiasis is common (up 
to 20-28%) among ADPKD patients53–56. Importantly, ADPKD patients with 
nephrolithiasis exhibit more severe polycystic kidney disease than those 
without57,58. Hyperoxaluria was found in 18% of ADPKD patients that are 
associated with nephrolithiasis suggesting the presence of CaOx crystals in some 
patients57. ADPKD patients also have high incidences of clinical gout (24%) and 
hyperuricemia (>60%)57,58, conditions that are associated with uric acid crystal 
formation in the kidneys. Elevated urinary uric acid levels are significantly 
correlated with faster disease progression in ADPKD59. Interestingly, ADPKD 
progresses more rapidly in males than females43. Likewise, male rats are naturally 
more prone to CaOx nephrolithiasis compared to female rats60. In the Han:SPRD 
rat model of ADPKD, male animals are affected more severely than females40,61. 
This dual gender bias in humans and rats may be consistent with a role of crystal 
deposition in accelerating ADPKD progression. 
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We have investigated the possible role of renal crystal deposition in affecting 
the rate of progression of PKD. In the process, we uncovered a previously 
unrecognized mechanism that facilitates the passage of microcrystals by tubule 
dilation. We report here that acute or chronic induction of CaOx nephrolithiasis in 
normal rats and mice leads to rapid activation of mTOR and Src/STAT3 signaling 
pathways accompanied by rapid dilation of tubule diameters along the entire 
tubular and collecting duct system. The same signaling pathways are known to be 
activated in ADPKD and contribute to renal cyst growth. After acute oxalate 
treatment, in approximately 7 days, CaOx crystals are cleared via the luminal 
space, these signaling pathways are inactivated and tubule diameters return to 
normal. Inhibition of mTOR by treatment with rapamycin significantly blocks 
tubule dilation and leads to renal accumulation of large CaOx crystal aggregates. 
These results suggest that tubule dilation is a purposeful mechanism in response to 
lodged microcrystals with the apparent goal of “flushing out” such crystals. This 
mechanism has not previously been recognized. Furthermore, we show that 
chronic oxalate exposure leads to tubular CaOx crystal deposition in male, but not 
female, animals of the Han:SPRD rat model of polycystic kidney disease. This 
leads to increased cystogenesis and significant worsening of disease progression in 
male, but not female, animals. Similarly, we report that a high phosphorous diet 
causes tubular CaP crystal deposition in the PCK rat model of polycystic kidney 
disease and leads to accelerated disease progression. Altogether, these results 
suggest a model in which tubular crystal deposition normally triggers a protective 
mechanism leading to temporary tubule dilation. In polycystic kidney disease, this 
mechanism could act as a “third hit” trigger that causes such dilated tubules to 
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“overshoot” to form cysts. If this mechanism affects the rate of disease 
progression in human ADPKD then it may consequently be possible to treat 
patients with relatively simple and well-established interventions known to reduce 
renal crystal formation in nephrolithiasis patients. These could include dietary 
changes, increased water intake and treatment with citrate as a calcium chelator. 
Intriguingly, increased water intake62,63 and citrate treatment64–66, respectively, 
have already been shown to be effective in rat models of PKD66 but the underlying 
mechanisms have remained elusive and it has not previously been considered that 
an effective reduction of renal crystal burden may be involved.  
B. Results 
Chronic CaOx nephrolithiasis leads to tubule dilation and activation of 
PKD-associated signaling pathways. 
To examine whether CaOx crystal deposition may lead to activation of PKD-
associated signaling pathways, a well-established mouse model of chronic CaOx 
nephrolithiasis was utilized. Animals deficient in the renal sodium-phosphate 
cotransporter Npt2a are calciuric and form CaOx crystal deposits in their kidneys 
when fed either hydroxy-proline or glyoxylate as metabolic precursors of 
oxalate67,68. As expected, treated animals exhibit numerous luminal CaOx crystal 
deposits visible by polarized light microscopy after 28 days (Fig. 2A). Significant 
tubule diameter dilation is very apparent throughout the renal parenchyma (Fig. 
2A). Analysis with segment-specific markers revealed that proximal tubules 
(LTL), connecting tubules (calbindin D28k) and collecting ducts (DBA) all 
exhibit dilation (Fig. 2B). Strikingly, dilated tubules are strongly positive for 
phosphorylated S6 (pS6) a downstream effector of the mTOR signaling pathway 
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indicating that mTOR is activated in these cells (Fig. 2C). In contrast, adjacent 
undilated tubules do not exhibit mTOR activation (Fig. 2C). Similarly, dilated 
tubules are also strongly positive for active, nuclear, tyrosine-phosphorylated 
STAT3 (Fig. 2C). Both mTOR and STAT3 have previously been shown to be 
activated in cyst-lining cells in human ADPKD and various rodent models of 
PKD, and to be drivers of renal cyst growth6–8,69–71. For comparison, kidneys from 
the Bpk mouse model of PKD were analyzed side-by-side and showed a degree of 
mTOR and STAT3 activation similar to that induced by nephrolithiasis (Fig. 2C). 
Dilated tubules also frequently contained Ki67-positive cells (Fig. 2D, E) 
indicating that chronic nephrolithiasis induces a proliferative response.  
Rapid activation of PKD-associated signaling pathways and tubule dilation 
in acute CaOx nephrolithiasis. 
To test whether tubule dilation and activation of PKD-associated signaling 
pathways are slow or fast responses to CaOx crystal deposition wild-type mice 
were treated acutely by a single intraperitoneal injection of sodium oxalate and 
analyzed at different time points thereafter. For unknown reasons, mice are 
relatively resistant to the formation of renal CaOx deposits67,68. A high dose of 
oxalate (0.7 mg/kg) was initially used to induce acute nephrolithiasis which led to 
rapid, abundant crystal deposition (Fig. 3A) appearing to be exclusively luminal 
(Fig. 3B). This coincided with rapid activation of mTOR and STAT3 at 3 hours 
and peaking at 1 day following treatment (Fig. 3C).  
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Figure 2: Glyoxalate treated Npt-KO Mice show tubule dilation and 
activation of ADPKD related pathways  
A.) H and E Stain: Sections of kidneys from glyoxylate treated Npt2a -/- 
mice under polarizing microscopy. B.) Segment specific staining of glyoxylate or 
hydroxy proline treated Npt2a -/- mice of LTL, DBA and Calbindin. C.) mTOR 
activity marker phospho-S6S235/236 and phospho-STAT3Y705 by 
immunofluorescence microscopy in the kidneys of treated Npt2a -/- mice. BPK 
mouse used as positive control. D.) Immunostaining for Ki67 in treated Npt2a -/- 
mice. E.) Quantification of Ki67 positive cells of the total number of DAPI 
stained nuclei with either glyoxylate or hydroxyl proline treatment. (Control n=3, 
n=3 for glyoxylate and n=2 for HP) ****= (>P=0.001) Error bars represent SD.  
 
High-dose oxalate treatment led to significant renal impairment and frequent death 
due to renal failure after several days. 
To induce a low, recoverable level of crystal burden we next administered 
via IP injection a low dose of oxalate (0.3 mg/kg) which resulted in CaOx crystal 
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deposition observed as early as 6 hours after injection, peaking at 24 hours, with 
most crystals excreted by 3 days (Fig. 3D). Abundant CaOx crystals are detectable 
in urine from 6 hours until 3 days after injection (data not shown). Tubule dilation 
can be seen as early as 1 day and peaking at 3 days (Fig. 3D). By seven days post 
injection all CaOx crystals are eliminated and tubule diameters return to normal 
(Fig. 3D). At all time points that CaOx crystals are visible they are found nearly 
exclusively in tubule lumens suggesting that the bulk of crystals are excreted with 
the urine via the luminal space (Fig. 3D). Dilated tubules exhibit activation of 
mTOR and STAT3 as early as 1 day after oxalate administration indicating that 
this is an early event coinciding with the process of tubule dilation (Fig. 3E). Mice 
survived this low-dose oxalate treatment and appeared to completely recover. 
However, some animals failed to form renal CaOx crystals consistent with the 
known resistance of mice to CaOx nephrolithiasis.  
 Calcium Oxalate Crystals Activates ADPKD Pathways and Promotes 
Dilatation in Wild-Type Rats 
To be able to quantify responses more accurately we next investigated the 
response to CaOx crystal deposition in a more robust experimental system. Rats 
are commonly used to experimentally induce CaOx nephrolithiasis because they 
are much more prone than mice to forming CaOx crystals following oxalate 
administration, are more resilient after crystal deposition and recover more 
consistently72–74. A single injection of sodium oxalate in rats again led to rapid 
renal CaOx crystal deposition within 6 hours accompanied by fast tubule dilation 
(Fig. 4A). After seven days, all crystals were cleared. Analysis using segment-
specific markers revealed that all investigated nephron segments undergo dilation,  
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Figure 3: Effect of sodium oxalate treatment on wild-type C57/B6 mice. 
A.) Whole kidney polarized microscopy image of oxalate treated (7mg/100g 
NaOX) mice. B.) High magnification polarized image of 1 day treated mouse of 
cortex and corticomedullary boundary (CMB). C.) Immunoblotting from wild type 
mouse kidneys of pS6 and pSTAT3 3 hours (n=4) and 1 day (n=9) post 7mg/100g 
oxalate treatment. D.) Polarized images of oxalate treated mice (3mg/100g NaOX) 
6 hours (n=4), 1 day (n=12), 3 days (n=8) and 7 days (n=13) post treatment.  E.) 
Immunofluorescence staining of phospho-S6S235/236 and phospho-STAT3Y705in 
NaOX (3mg/100g) treated mice.  
 
  12 
namely proximal tubules, the thick ascending limb, connecting tubules and 
collecting ducts (Fig. 4B). Quantification of the tubule outer diameters and the 
lumen diameters revealed that both parameters increased, peaking at day 3 and 
largely returned to normal by day 7 (Figs. 4C-F). The tubule diameter increase is 
accompanied by a decrease in cell height (Fig.4G). mTOR and Src/STAT3 
signaling were activated in dilated tubules at six hours following injection, 
reaching a peak at three days (Fig 4H, I). Proliferation was observed to begin as 
early as 6 hours following oxalate administration and peaking at 3 days (Fig. 4J, 
K). A non-significant increase in the number of apoptotic tubule cells was 
observed (Fig. 4L) indicating that this level of crystal burden does not cause 
extensive cell death.  
Altogether, these results indicate that both mice and rats respond to renal 
CaOx crystal deposition by rapidly activating mTOR and STAT3 signaling, 
dilating tubule diameters throughout the nephron, initiating a proliferative 
response, and clearing crystals via the luminal space for urinary excretion. 
mTOR Inhibition blunts tubule dilation and impairs crystal excretion. 
Next, we investigated whether mTOR activation is necessary for the dilation 
of tubules in response to lodged CaOx crystals. Rats were treated with rapamycin 
to inhibit mTOR, followed by acute oxalate challenge. As shown in Fig. 5A,B, 
rapamycin treatment prevents mTOR activation as anticipated in Fig. 1. mTOR 
inhibition did not prevent the activation of Src and STAT3 (Fig. 5A,B) indicating 
that these pathways are not downstream of mTOR. Rapamycin treatment 
inhibited, but did not fully suppress, proliferation as measured by Ki-67 (Fig. 5C, 
Supplemental Fig. 2). 
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Figure 4: Acute oxalate treatment causes tubule dilation and PKD related 
pathway activation in wild-type Sprague-Dawley rats 
 A.) Polarized microscopy images of animals treated with 7mg/100g NaOx after 6 
(n=5), 24 hours (n=5), 3 day (n=5) and 7 days (n=3) respectively. B.) Segment 
specific immunostaining of kidney sections; collecting ducts (AQP2), proximal 
tubules (AQP1), connecting tubules (Calbindin D28K), and thin ascending loop of 
Henle (Tam-Horsfall Protein) from treated rats. C-F.) Measurements of lumen and 
tubule diameters of AQP1 (C), THP (D), Calbindin (E) and AQP2 (F) segment 
specific markers.   
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Figure 4: (continued) G.) Cell height measurements from all segments in C-F at 
6 hours following treatment. H.) Immunoblotting of total kidney lysates from 
treated rats.  I.) Immunofluorescence staining of treated kidneys for phospho-
S6S235/236 and phospho-STAT3Y705 6 hours, 1 day, 3 days and 7 days after 
injection. J.) Ki67 immunostaining of treated rat kidney sections. K.) 
Quantification of Ki67 positive from J. L.)  Control and treated rats was evaluated 
for the presence of apoptotic cells by counting the TUNEL positive cells in each 
field and normalizing them to the number of nuclei in each field. Error bars 
represent SD, = (>P=0.0001) 
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Remarkably, mTOR inhibition blunted the extent of tubule dilation after oxalate 
challenge (Fig. 5D). 
 Eventually, all investigated tubule segments were able to dilate in 
rapamycin-treated animals but to a diminished degree (Fig. 5E) suggesting that 
mTOR activity is at least partially required for tubule dilation.  
 
Figure 5: Legend on page 16. 
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mTOR inhibition led to the striking accumulation of large aggregates of 
CaOx crystals in tubules located in a distinct band at the corticomedullary 
boundary (Fig. 5F-H). Immuno-staining with segment specific markers 
demonstrated that these clusters of CaOx crystals primarily accumulate in the 
lumens of the thin descending limb of Henle and the preceding segment of the 
proximal tubule (Fig. 5H). Crystal aggregates are still prominently observed at this 
border in rapamycin-treated animals at 3 days after treatment (Fig. 5F, I). During 
this course, crystals are markedly depleted in the renal cortex in rapamycin-treated 
animals vs. control animals (Fig. 5F, I). These results suggest that mTOR 
inhibition leads to inhibition of tubule dilation, which creates a “bottleneck” at the 
point of the nephron that naturally exhibits the smallest lumen diameter, the thin 
descending limb of Henle. This leads to accumulation of CaOx crystals at this 
location, which, in turn, prevents the efficient transport of crystals back towards 
the distal convoluted tubule and the collecting ducts in the renal cortex.  
Figure 5: Rapamycin diminishes effect of oxalate treatment on wild type 
Sprague Dawley rats by inhibiting mTOR pathway  
A.) Immunoblotting of NaOX treated rat’s kidney lysates. B.) Immunostaining of 
SPRD rats 6 hours after treatment with NaOx, with or without rapamycin 
pretreatment. C.) Quantification of Ki67 positive cells in NaOx and rapamycin 
treated rats. D.) Immunostaining of kidney sections following oxalate treatment, 
including collecting ducts, proximal tubules by staining with AQP1 and AQP2 
respectively E.) Measurement of tubular and lumen diameters in oxalate treated 
rats after rapamycin treatment. = (>P=.0001) F.) Polarized images of whole 
kidneys after 6 hours and 3 days following oxalate treatment G.) High 
magnification polarized images showing oxalate crystal aggregates 6 hours 
following oxalate treatment with and without rapamycin. CMB=corticomedullary 
boundary H.) Pizzolato staining together with segment specific marker in 
rapamycin treated rats. Arrows denote crystal location. I.) Quantification of 
deposited crystals in oxalate treated rats 6 hours and 3 days after oxalate treatment 
with and without rapamycin. J.) Quantification of crystal size in oxalate treated 
rats with and without rapamycin. Error bars represent SD 
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Altogether, these findings suggest that tubule dilation is a purposeful response 
to lodged renal crystals, that PKD-related signaling pathways are involved in this 
process, and that inhibition of this system leads to inefficient clearance of crystals. 
To our knowledge, this mechanism of crystal clearance has not previously been 
reported. 
CaOx crystal burden leads to increased disease severity in the Han:SPRD 
rat model of polycystic kidney disease. 
 We hypothesized that renal crystal deposition may accelerate disease 
progression of polycystic kidney disease. To investigate this possibility we chose 
the well-characterized Han:SPRD (Cy/+) rat model of PKD30,31 because: (a) as a 
rat model, these animals are more susceptible to CaOx nephrolithiasis than mice; 
(b) this is a slowly progressive model which may allow for the possibility that 
disease progression could be accelerated; and (c) male, heterozygous (Cy/+) 
animals in this model exhibit more severe disease progression than female Cy/+ 
animals which would be consistent with the known propensity of male rats to be 
more susceptible to renal CaOx crystal deposition than female rats. Animals were 
treated from 3-8 weeks of age with 0.75% ethylene glycol in the drinking water 
(Fig. 6A) for exposure to a chronic burden of CaOx crystals.  
 Ethylene glycol is metabolized to oxalate leading to hyperoxaluria, and this 
treatment has previously been shown to lead to CaOx nephrolithiasis in male but 
not female rats52,75,76. Numerous CaOx crystals are readily detectable in lumens of 
cysts and dilated tubules in male Cy/+ rats but not in female Cy/+ rats (Fig. 6B). 
Remarkably, male Cy/+ rats treated with ethylene glycol exhibit significantly 
increased renal cystic disease as compared to untreated animals (Fig. 6B). In 
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contrast, disease progression is unaffected by ethylene glycol treatment in female 
Cy/+ rats. The two-kidney weight/body weight ratio (Fig. 6C) and renal cystic area 
(Fig. 6D) are both significantly increased in ethylene glycol-treated male Cy/+ rats 
vs. controls. A significant increase in cyst number (Fig. 6E), but not average cyst 
size (Fig. 6F), is also observed suggesting that the increased disease severity is 
largely due to an increase in cystogenesis.  
 
Figure 6: Ethylene Glycol treatment of Han rats exacerbates disease 
progression  
A.) Rats were given 0.75% ethylene glycol in their drinking water starting at week 
3 until 8 weeks of age. B.) Hematoxylin and Eosin stained kidney sections were 
visualized by light and polarized microscopy. C.) 2-Kidney/Bodyweight ratio from 
ethylene glycol treated and untreated rats. D.) Cystic Index of treated and 
untreated rats. ***>P=0.001. E.) Cysts counted from treated and untreated 
animals male Cy/+ rats. *>P=0.05 F.) Quantification of cyst sizes in ethylene 
glycol treated and untreated male Cy/+ rats. G.) Immunostaining with segment 
specific markers for proximal tubule (AQP1) in both ethylene glycol treated and 
untreated male Cy/+ rats. Error bars represent SD 
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Cysts are known to arise from the proximal tubule in Cy/+ rats40. Immuno-
staining with segment-specific markers revealed that essentially all cysts are of 
proximal tubule origin in both ethylene glycol-treated and untreated male Cy/+ 
rats (Fig. 6G). This indicates that CaOx nephrolithiasis leads to increased 
cystogenesis only in the tubule segment that is predisposed to cyst formation in 
this model. Since female Cy/+ rats are exposed to the same ethylene glycol 
regimen as male Cy/+ rats but are resistant to renal CaOx crystal deposition and 
exhibit no altered cystic disease progression we conclude that the effect of 
ethylene glycol treatment in male Cy/+ rats is not due to any chemical action of 
ethylene glycol or oxalate per se but is due to the physical interaction of CaOx 
crystals with the renal epithelium. 
Altogether, these results suggest that renal crystal burden can exacerbate 
cystogenesis leading to overall acceleration of PKD progression. 
 High phosphate diet leads to calcium phosphate crystal deposition and 
increased disease progression in the PCK rat model. 
Next, we investigated whether the observed effect of renal crystal deposition 
on PKD progression is specific to CaOx crystals or may also be caused by crystals 
of a different chemical composition, and perhaps at a different location within the 
tubular/collecting duct system. We investigated the PCK rat model, an 
orthologous model to autosomal-recessive PKD that is due to a mutation in the 
Pkhd1 gene77. In addition to liver cysts, PCK rats develop renal cysts of 
predominantly collecting duct origin which exhibit increased activity of 
mTOR78,79, Src80 and STAT330. 
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Figure 7: High phosphate diet induces calcium phosphate deposition and 
deterioration of disease progression in PCK rat model. 
A.) Von Kossa staining in male and female PCK rats on control and high 
phosphate diet (HPD). B.) Quantification of CaP deposition in HPD male and 
female PCK rats. C.) 2-Kidney/Bodyweight ratio of control and HPD female and 
male rats. D.) Cystic index in HPD fed female and male rats E.) Blood urea 
nitrogen levels of control and HPD male and female rats. F.) Segment specific 
staining of HPD PCK rats shows appearance of new cortical cysts, which are 
originated from proximal tubules (AQP1 positive). G.) immunofluorescence 
staining of phospho-S6S235/236 shows that the new cysts are highly positive for 
pS6. H.) Von Kossa and AQP1 and AQP2 costained sections indicate that crystals 
are located in the descending loop of Henle (AQP1 positive) not in the collecting 
ducts. Arrows denote crystals. Error bars represent SD. Scale bars are 100 μm (B), 
or 50 μm (C,D). 
 
In contrast to CaOx nephrolithiasis that affects male humans and rats more 
severely than females, the opposite is true for CaP nephrolithiasis60,81. Dietary 
intake of phosphate varies widely among individuals and can influence the 
occurrence of CaP nephrolithiasis. To determine if increased dietary phosphate 
may affect PKD disease progression, male and female PCK rats were fed identical 
artificial diets except for the phosphorous content (control 0.6%; low phosphate 
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diet, LPD 0.2%; high phosphate diet, HPD 1.2%) between 3 and 10 weeks of age. 
LDP caused growth retardation compared to the control diet, but did not change 
cyst area or fibrosis (data not shown). 
HPD led to a marked increase in CaP crystal deposits in tubule lumens along 
the corticomedullary junction, to a larger extent in female than in male animals 
(Fig. 7A, E). The location of CaP crystal deposition at the corticomedullary 
junction is consistent with previous findings60. Immunostaining for segment-
specific markers revealed that CaP deposits occurred primarily in AQP1-positive 
tubules at the transition between proximal tubules and the thin descending loop of 
Henle (Fig. 7C). Strikingly, HPD led to a worse progression of PKD, to a larger 
extent in female than male animals. The two-kidney weight/body weight ratios 
(Fig. 7F) and cysts scores (Fig. 7G) were significantly increased in both male and 
female rats on HPD compared to controls (see also Suppl. Table 1). Female PCK 
rats in the HPD group also exhibited increased serum BUN values indicating 
impairment of renal function (Fig. 7H). In addition to an increase in AQP2-
positive, collecting duct-derived cysts, HPD also led to the emergence of AQP1-
positive and presumably proximal tubule-derived cysts (Fig. 7B). There was no 
effect on the liver cystic disease (Suppl. Table 1) suggesting that the effect of HPD 
is kidney specific. Altogether, these results show that a dietary-induced increase in 
tubular CaP precipitates leads to increased cystogenesis and PKD disease 
progression in this model. This location is consistent with the previous finding 
that CaP crystal deposition in female rats was generally localized to the 
corticomedullary junction60, the location of the transition between proximal 
tubules and the loop of Henle.  
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Figure 8: Human Primary Hyperoxaluric kidneys express PKD related 
signals 
A.) Polarized images of Hematoxylin and Eosin stained kidney sections from a 
patient with primary hyperoxaluria type 1 (PH I) exhibit calcification of the kidney 
as evident by presence of birefringent crystal deposition, with tubular crystal 
deposition (n=3). B.) Immunostaining of PKD and PHI kidney sections for 
phospho-S6S235/236 and phospho-STAT3Y705 shows strong signals for pS6 and 
pSTAT3 in the calcium deposited tubules (PH I) as well as dilated tubules and 
cysts in the human ADPKD samples. 
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HPD also caused a worse progression of polycystic kidney disease, again to a 
larger extent in female than male animals. The two-kidney weight/body weight 
ratios (Fig. 7C) and cysts scores (Fig. 6D) were significantly increased in both 
male and female rats on HPD compared to controls. Female PCK rats in the HPD 
group also exhibited increased serum BUN values indicating impairment of renal 
function (Fig. 7E). Segment specific marker immunostaining shows that the cysts 
are exclusively derived from the proximal tubules (Fig. 7F) and CaP crystals are 
deposited in the AQP1 positive cells (Fig. 7G) which stain the proximal tubules 
and thin descending loop of Henle. There was no effect on the liver cystic disease 
(not shown) suggesting that the effect of HPD is kidney specific.  
 Tubule dilation and activation of PKD-associated signaling pathways in 
human primary hyperoxaluria 
To determine is these results can be validated our findings in human disease, 
we evaluated renal tissues from primary hyperoxaluria type 1 (PH1) patients. In 
PH1, a genetic defect leads to deficient glyoxylate metabolism, causing 
hyperoxaluria, CaOx nephrolithiasis and eventually renal failure. Renal biopsy 
specimens from PH1 patients exhibit CaOx crystal deposition and tubule dilation 
(Fig. 8A). Both mTOR and STAT3 pathways are strongly activated in PH1 to a 
degree comparable that seen in cysts in human ADPKD (Fig. 8B). This result 
suggests that tubular crystal deposition leads to activation of PKD-associated 
signaling pathways and tubule dilation in both rodents and humans. 
Altogether, these findings are consistent with the conclusion that renal crystal 
deposition triggers accelerated progression of polycystic kidney disease by 
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activation of an inherent, renoprotective mechanism that has the purpose of 
facilitating the excretion of tubular crystals.  
C.  Discussion 
The results presented here point to a previously unrecognized renoprotective 
mechanism that involves the purposeful dilation of renal tubules in response to 
lodged microcrystals with the apparent purpose of facilitating the “flushing out” of 
such crystals along the luminal space for excretion with the urine. Furthermore, 
our results suggest that this renoprotective mechanism acts as a “third-hit” trigger 
leading to accelerated disease progression in PKD. 
Millions of microscopic crystals may form in human kidneys daily, are 
transported through the tubules, and excreted safely with the urine49,82. The 
presence of several types of crystals (incl. CaOx, CaP, struvite, uric acid) in urine 
is considered normal and up to a quarter of fresh urines from normal subjects even 
exhibit overt crystalluria51 without immediate detriment to kidney function. Diets 
and numerous pathologies greatly influence the range of crystal burden that the 
kidneys experience. Without effective mechanisms to prevent excessive crystal 
growth and retention in tubular lumens, tubules would rapidly become occluded 
and renal function would seize. Protective mechanisms include renal regulators of 
crystal nucleation and growth such as osteopontin, nephrocalcin and THP50. 
However, the occurrence of nephrocalcinosis and nephrolithiasis indicates that 
these mechanisms are not always completely effective, and that crystals can 
sporadically lodge in tubule lumens due to aberrantly fast growth or aggregation. It 
is poorly understood how sporadically lodged micro-crystals are cleared from 
kidneys. One observed mechanism is that some crystals can somehow cross the 
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epithelial barrier into the interstitial space presumably via endocytosis52. However, 
their subsequent fate is uncertain and this may be a slow process occurring in the 
time-frame of weeks83. It is difficult to see how such a cumbersome and disruptive 
interstitial mechanism could accomplish effective clearance of more than a small 
amount of lodged crystals at a time. What is known, is that, eventually, renal 
crystal deposition can lead to pathological nephrocalcinosis or nephrolithiasis 
including tubule occlusion and the formation of macroscopic kidney stones which 
are most commonly found in the urinary space attached to the renal papilla83–86. 
Roughly 70-80% of all kidney stones in humans are composed of CaOx. 
 Even though tubule dilation is universally observed in many forms of 
nephrocalcinosis and nephrolithiasis in humans and animal models87 this 
phenomenon has not been considered of anything more than a secondary 
consequence to cell injury. Our results suggest that CaOx crystal deposition leads 
to very rapid activation of mTOR and Src/STAT3 signaling in tubule epithelial 
cells accompanied by equally rapid dilation of tubule diameters. While occasional 
cell damage can be observed – particularly when cells are in direct contact with a 
lodged crystal - the rapid dilation response occurs in most tubule segments up- or 
downstream of any lodged crystals without any apparent evidence of cell damage 
or death. Our results suggest that segments all along an affected nephron will 
dilate in response to lodged CaOx crystals, whether a crystal is detectable in the 
particular segment under observation or not.  
We have chosen experimental conditions of oxalate challenge that lead to 
a moderate degree of initial deposition of CaOx crystals, which can eventually be 
completely resolved by the kidneys. This level of crystal burden does not lead to 
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widespread tissue destruction or renal failure, and was meant to mimic the 
situation that kidneys may frequently be exposed to under non-pathological 
conditions. We find that CaOx crystals under these conditions are located almost 
exclusively in tubule lumens from the moment they first occur until they are 
cleared. Interstitial crystals are very rarely observed. This suggests that the vast 
majority of crystals are cleared via the luminal space and excreted with the urine. 
The distribution of acutely induced CaOx crystals indicates that crystals initially 
form in the proximal tubule and are then passed all along the tubular system. This 
is in agreement with previous studies in rats87 and primary hyperoxaluria 
patients88. It is intuitive that dilation along the entire length of the nephron would 
facilitate this mechanism of “flushing out” crystals and counter their 
accumulation. Indeed, we find that mTOR inhibition with rapamycin blunts the 
ability of tubules to dilate in response to CaOx crystals and leads to accumulation 
of crystal aggregates, primarily at the transition from the proximal tubule to the 
descending loop of Henle. These transitions are located in the corticomedullary 
boundary and appear to represent a bottleneck for the passage of microcrystals, 
presumably due to the abrupt narrowing of tubule diameters. This is consistent 
with the previous finding of CaOx crystal aggregates in the same location in 
primary hyperoxaluria patients88. 
We propose that tubule dilation is a purposeful mechanism that involves 
activation of mTOR and STAT3 signaling pathways. Several possible scenarios 
can be envisioned for how a CaOx crystal may trigger a dilation response in tubule 
epithelial cells. In a possible short-range mechanism, the direct physical contact of 
a crystal with the apical surface of epithelial cells may be required while the 
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crystal passes through a tubule. This model, however, would not explain how a 
tubule segment downstream of a lodged crystal would be able to detect its 
presence and dilate in response. Alternatively, in a possible long-range 
mechanism, a lodged crystal may activate a response both up- and downstream of 
its location by affecting the fluid flow in the given nephron due to partial or 
complete occlusion. Other possible long-range mechanisms may involve diffusible 
factors – such as growth factors, cytokines or other signaling molecules – that may 
be secreted by injured epithelial cells in direct contact with a crystal or mechanical 
stretching sensed by the tubular cells. Primary cilia may potentially play a role in 
both short- and long-range mechanisms by sensing of crystals, signaling factors 
and/or fluid flow. Future work is required to investigate these possibilities.  
Our results suggest that tubule dilation involves - and at least partially 
requires - activation of mTOR signaling. mTOR functions in two complexes, 
mTORC1 and mTORC2, which regulate numerous cellular functions including 
cell size, proliferation and the actin cytoskeleton89,90. It is possible that an mTOR-
dependent cell size increase may play a role in tubule dilation. Our finding that 
dilation of tubule diameters comes at the expense of cell height indicates that a 
change in cell shape is important raising the possibility that mTOR-mediated 
changes in the actin cytoskeleton may play a role in this process. Interestingly, 
Pkd1–/– cyst-lining epithelial cells also exhibit a change in shape from cuboidal to 
flat91 which suggests that polycystin-1 may have a role in cell shape regulation. It 
is important to note that PC1 can regulate mTOR activity8,92 suggesting a coupled 
pathway. It was also recently shown that osteoblastic cells react to stretch by PC1-
dependent activation of STAT393. Whether PC1 plays a direct role in the 
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regulation of mTOR and/or STAT3 signaling during the dilation-response to 
crystal deposition shown here remains to be investigated. 
In addition to a relatively rapid response of dilation of tubule diameters, 
peaking at 24 hours, we also observe a slower induction of proliferation, peaking 
at 3 days after acute oxalate challenge. The later proliferative phase may aid in the 
replacement of damaged cells. Consistent with this view, it has been found that 
CaOx crystals can lead to necroptosis of tubule epithelial cells94. mTOR activation 
appears to be involved in the proliferative response because rapamycin treatment 
strongly inhibits proliferation of tubule cells in response to CaOx crystal 
deposition (Fig. 4C). Our results, however, suggest that mTOR and STAT3 
activation are independent of each other because STAT3 is still activated in the 
presence of rapamycin (Fig. A, B).  
In the natural progression of PKD, tubule dilation is the first step towards 
cystogenesis. Recent evidence from several laboratories clearly indicates that 
genetic inactivation of Pkd1, or ablation of primary cilia in mice with mature 
kidneys, is insufficient to trigger cystogenesis. However, subsequent renal insults 
can trigger rapid cystogenesis in such models, which has led to the now widely 
accepted view that a “third-hit” mechanism determines the rate of cystogenesis 
and progression in PKD. Experimentally, ischemia-reperfusion injury, nephrotoxic 
injury and compensatory hypertrophy after uninephrecotomy have been shown to 
act as third-hit triggers in preconditioned mice. Given that such types of renal 
insults are rare in humans, they appear unlikely to explain the relatively steady rate 
of progression in human ADPKD. Our results suggest that activation of the 
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renoprotective mechanism in response to crystal deposition described here can act 
as a third-hit trigger and accelerate the rate of PKD progression. 
We found that tubule dilation in response to crystal deposition involves 
activation of the same signaling pathways, mTOR and Src/STAT3, that have 
previously been shown to be involved in PKD. In this process, mTOR-dependent 
proliferation is also activated, as it is in PKD. In two rat models of PKD we 
showed that conditions that lead to renal deposition of different types of crystals 
also lead to increased cystogenesis and accelerated disease progression. These rat 
models are genetically independent of each other and exhibit different disease 
phenotypes. The gene coding for Samcystin, a protein expressed in proximal 
tubule cells95, is affected in the Han:SPRD rat model which leads to cysts of 
proximal tubule origin16. In contrast, the gene coding for fibrocystin is affected in 
the PCK rat model77 which leads to cysts of collecting duct origin. The functions 
of Samcystin and fibrocystin are incompletely understood. Samcystin interacts 
with Bicc196 which, is an RNA binding protein that localizes and silences bound 
mRNA97 and acts both downstream and upstream of the polycystins98,99, the 
proteins affected in human ADPKD. Fibrocystin, which is mutated in human 
ARPKD, co-localizes with the polycystins on primary cilia, physically interacts 
with polycystin-236, and has been shown to regulate mTOR activity100 similar to 
polycystin-18. It is likely that most or all the ciliopathy-associated proteins 
converge on the same molecular pathways that lead to renal cyst growth. In human 
ADPKD, cysts arise from all nephron segments, and therefore the PCK and 
Han:SPRD models may be regarded as models for subsets of cysts that arise from 
distinct tubule segments. Nevertheless, despite this genetic and phenotypic 
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distinctness between these two models, and even though we induced deposition of 
crystals of different chemical compositions (CaP vs. CaOx) we observed an 
increase in cystogenesis in both cases. These results suggest that renal crystal 
deposition can lead to cystogenesis in a variety of tubule segments and in a variety 
of genetically predisposed models. 
Our results indicate that the observed increase in cystogenesis was 
dependent on the physical presence of tubular crystals as opposed to any effects of 
oxalate or phosphate per se. Treatment of male and female Han:SPRD rats with 
the same dose of ethylene glycol resulted only in crystal deposition and increased 
cystogenesis in males but not females. Similarly, the effect of a high phosphate 
diet on CaP precipitation correlated with increased cyst growth preferentially in 
female rather than male PCK rats. This suggests that increased cystogenesis is due 
to mechanical effects of crystals, such as possibly disruption of fluid flow or 
physical cell damage. 
Based on these results, we propose that renal crystal deposition may affect 
disease progression in human ADPKD. Although there is no definitive study, a 
link between ADPKD progression and renal crystal burden has emerged based on 
numerous correlative studies. Generally, in these studies it is speculated that 
increased abnormalities in tissue architecture and/or metabolic abnormalities 
during ADPKD progression may be the cause of increased nephrolithiasis. 
However, the opposite may be the case; i.e. that increased crystal burden leads to 
accelerated ADPKD progression. It is also possible that ADPKD progression and 
nephrolithiasis positively reinforce each other leading to a vicious cycle. 
  31 
If nephrolithiasis accelerates ADPKD, then treatments that reduce renal crystal 
formation and deposition may slow progression in ADPKD. Such treatments 
typically are dietary changes to avoid foods rich in oxalate, phosphate, and uric 
acid precursors, increased water intake, and supplementation with citrate as a 
chelator of calcium to reduce CaOx and CaP precipitation. 
Remarkably, increased water intake has already been shown to effectively 
slow PKD progression in the PCK rat27. The mechanism of the protective effect is 
unknown, but was hypothesized to involve a decrease in vasopressin signaling. 
We hypothesize that the protective effect may instead (or in addition to) be due to 
increased urine output and dilution of solutes, which decreases the risk of tubular 
crystal deposition. Increased water intake is commonly prescribed for the 
treatment of recurring nephrolithiasis in humans.  
Even more remarkable, citrate treatment has been shown to be highly effective 
in reducing cyst growth, preserving renal function and extending life span in the 
Han:SPRD rat model64–66. The mechanism of this effect remained unexplained 
and these investigators speculated that the effect may be due to alkalization of the 
urinary pH. In contrast, we hypothesize that the beneficial effect of citrate 
observed in those early studies was due to citrate’s action as a chelator and 
inhibitor of calcium crystal formation. For this reason, citrate is a standard 
treatment for patients with recurring calcium nephrolithiasis101. Unfortunately, 
presumably due to the lack of a mechanistic explanation, citrate has never been 
tested in clinical trials in ADPKD patients. Citrate was found to be ineffective in 
the pcy mouse model of PKD102,103. However, this was likely due to the fact that 
tubular crystals play no role in the cystogenesis of this, or any other, mouse model 
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because mice are naturally highly resistant to CaOx crystal precipitation. 
Furthermore, cystogenesis in most genetic mouse models of PKD is pre-
determined by the genetic abnormality and does not depend on any third hit 
trigger. Consistent with this, no evidence for lithogenic risk factors were found in 
a Pkd1 mouse model104.  
D. Methods 
Animals 
All animal experiments were conducted under the supervision and approval of the 
UCSB Institutional Animal Care and Use Committee (IACUC). Animals 
maintained and produced at UCSB were housed in the animal resource center with 
a 12-hour light/dark cycle, allowed free access to water and standard chow with 
wood based bedding. When available, breeders were provided with housing 
enrichment in the form of cardboard tubes (rats) or plastic housing (mice).  All 
animals were weaned at 3 weeks of age and separated by sex. Genotype of animals 
was not used to sort animals into cages prior to treatment. All animals were 
monitored for signs of distress during the course of the study including: poor 
grooming, changes in mobility, abnormal posture, abnormal gait and unkempt 
appearance. Individual animals were treated as the experimental unit for the 
purposes of this study. The researchers performing the experiments were not 
blinded to the treatment of animals. 
Sample Size 
Sample size was determined using prior knowledge from experiments performed 
in our lab using polycystic animals69,105.  
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NPT2a Deficient Mice 
4-6 month-old Npt2a-KO mice weighing 18-30g were given 1.5% glyoxylate or 
1.25% ethylene glycol mixed with chow for 28 days to induce hyperoxaluria after 
which mice were sacrificed. By day 7 of the experiment Npt2a -/- mice became 
hyperoxaluric, and remained so throughout the experimental period. 
Oxalate Treatment 
All injections of oxalate were performed between 8-10AM in the animal resource 
center via intraperitoneal administration to control the dose of oxalate. 
Mice 
8-10 week-old male and female C57/B6 mice weighing between 20-30g were 
purchased from Charles Rivers laboratories and allowed 1 week to acclimate to 
our animal facilities. Mice were challenged with a single intraperitoneal injection 
of 0.22M sodium oxalate dissolved in 0.9% saline, sterile filtered and 
administered at 3mg/100g (low dose) and harvested at 6 hours (n=4), 1 day 
(n=12), 3 day (n=8) and 7 days (n=10); or 7mg/100g (high dose) at 3 hours (n=4) 
and 1 day (n=9) to produce oxalate crystals. Control animals included n=6 males 
and n=5 females treated with saline. Low dose animal trials were conducted in 5 
separate experiments and high dose trials were conducted in 2 separate 
experiments. Animals that did not exhibit crystal deposition were not included in 
analyses of crystal effects. 
Sprague Dawley Rats 
8-week-old Sprague Dawley rats weighing between 200-300g were purchased 
from Charles Rivers laboratories and allowed 1 week to acclimate to our animal 
facilities. Prior to treatment, animals were grouped into 2-3 per cage and treated 
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identically. Rats were challenged with a single intraperitoneal injection of 0.22M 
sodium oxalate dissolved in 0.9% saline, sterile filtered and administered at 
7mg/100g and harvested 6 hours (n=5), 1 day (n=5), 3 days (n=5), or 7 days (n=3) 
to produce oxalate crystals. 6 hour, 1 day and 3 day treatments were conducted 
over 3 experiments and once for 7 days. Rapamycin treatment- Prior to oxalate 
challenge, Sprague Dawley rats were treated with 2mg/kg rapamycin (LC 
Laboratories) dissolved in DMSO 18 hours prior to oxalate administration, then 
24 hours after oxalate administration and finally 72 hours following oxalate 
administration. Controls received DMSO only. Rapamycin treated animals were 
treated with oxalate as described above and harvested 6 hours (n=5), 1 day (n=5), 
3 days (n=5), or 7 days (n=2). 6 hour, 1 day and 3 day treatments were conducted 
over 3 experiments and once for 7 days. 5 age-matched untreated controls were 
used for this experiment. Animals that did not exhibit crystal deposition were not 
included in analyses of crystal effects. 
Han:SPRD Rats 
The Han:SPRD rats were graciously contributed by Benjamin Cowley and 
transferred to the animal resource center at the University California Santa 
Barbara.  
Genotyping 
Rats were genotyped using a known polymorphism in the Ansk6 (Pkdr1) gene. 
PCR coupled to restriction digest was used detect a C to T transition responsible 
for PKD in the Han:SPRD rats. Normal and Cy/+ rats were genotyped using a 
PCR restriction fragment length polymorphism method as described previously by 
Brown et al.16. DNA was extracted from a small piece of ear of each rat and PCR 
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products were obtained from each DNA sample. Primers for rat Samcystin were as 
follows: sense primer: CTA GAA GCC TCA GTG ACC CC; anti-sense primer: 
CAG CGT GTG AAC AAG GTA GG. Amplification products were digested by 
Msp1 (Fermentas) at 37°C for 1 h. Digested PCR products were resolved on an 
agarose gel, producing bands at 157 and 85 bp; 242, 157, and 85 bp; and 242 bp 
for +/+, Cy/+, and Cy/Cy rats, respectively. 
Ethylene Glycol Administration 
Ethylene glycol (Sigma-Aldrich) was prepared at 0.75% in purified water and 
administered ad libidum from 3 to 8 weeks of age. Animals treated for this 
experiment include; 9 wild-type male rats (264.0g±22.9), 9 Cy/+ male rats 
(251.1g±21.6), 6 wild-type female rats (202.8g±17.4), 7 Cy/+ female rats 
(188.9g±14.3). Untreated animals include; 4 wild-type male rats (274.3g±16), 5 
Cy/+ male rats (267.3g±16.6) and 5 wild-type female rats (192g±12.1), 5 Cy/+ 
female rats (193.8g±13.4). 
PCK Rats 
Male and female PCK rats were fed identical diets except for phosphorous 
content. 10 male rats (387.2g±20.0) and 10 female rats (245.3g±12.8) were given 
0.6% (Intermediate phosphorous) or 10 male rats (344.7g±12.0) and 10 female 
rats (227.6g±8.4) were given 1.2% (High phosphorous) diets from 3 to 10 weeks 
of age.  
Hematoxylin and Eosin Staining 
Paraffin embedded tissues were cut into 5µM sections using a microtome and 
placed onto Superfrost+ slides (Fischer Scientific).  These sections were then 
dried overnight on a hot plate at 37°C before moving through a rehydration series 
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(xylene, 100%EtOh, 95%EtOH, 70%EtOH). Slides were then rinsed in distilled 
water briefly, immersed in hematoxylin for 45secs and rinsed with tap water until 
no more hematoxylin residue was observed. The slides were then dipped 10 times 
in 95% EtOH before placed in Eosin Y solution for 45secs. The slides were then 
dipped 10 times in 95% EtOH, 10 times in 100% EtOH twice and xylene for 5 
minutes twice. After which the slides were sealed using Permount mounting 
media (Fischer) and covered with a coverslip.  
Von Kossa Staining 
Following rehydration in ethanol, samples were incubated in 5% silver nitrate 
solution for 30 minutes exposed to UV light. Samples were then rinsed in distilled 
water and incubated in 5% thiosulfate solution for 3 minutes followed by a 2-
minute rinse in running tap water and 2 rinses in distilled water.   
Immunofluorescence 
Formalin fixed, paraffin embedded kidneys were sectioned to 5µm thickness using 
a microtome. Samples were then rehydrated as described for H and E staining. 
Following rehydration slides were washed in TBS and boiled in trisodium citrate 
at pH 6 for 5 minutes in a pressure cooker. Once cooled the slides were washed 
twice by TBST (each 5 minutes) and blocked by blocking buffer (1% BSA, 0.1% 
Fish skin gelatin, 0.05% Sodium Azide in TBST) at 37˚C for 30 minutes. After 
which the blocking buffer was aspirated and the slides were incubated with 
primary antibody diluted 1:200 in blocking buffer overnight at 4˚C (Rabbit anti-
pS6S235/236, Cell Signaling #4858; Rabbit anti-pSTAT3Y705, Cell Signaling #9145; 
Rabbit anti-aquaporin-1, Millipore AB2219; Goat anti-aquaporin-2, Santa Cruz 
sc-9880; Mouse anti-Calbindin D-28K, Sigma C9848; Rabbit anti-Tamm-Horsfall 
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protein, Santa Cruz sc020631; Rabbit-anti-Ki-67, BD Pharmingen #550609). The 
following day, to quench background auto-fluorescence, the slides were incubated 
with 1% Sudan Black diluted in 70% ethanol for 20mins which, followed by two 
washes in TBST each for 5 minutes while gently agitated. The slides were then 
incubated with a species-specific fluorescently conjugated 2˚ antibody diluted in 
blocking buffer at 37˚C for one hour (Goat anti-Rabbit-DyLight 488 and 594, 
#35552 and #35560, ThermoFischer; Goat anti-mouse-DyLight 488, 
ThermoFischer #35502; anti-LTL-FITC, Vector FL-1321; anti-DBA-Rhodamine, 
Vector RL-1032). The slides were next washed in TBST 3 times for 5 minutes 
with agitation followed by fixation using 4% paraformaldehyde for 5 minutes and 
finally washed in TBST. Slides were then covered with ProLong w/DAPI 
(ThermoFischer) and covered with a coverslip. 
Cystic Index 
Whole kidney sections stained with Hematoxylin and Eosin were used to 
determine cystic indices. Sections were analyzed using ImageJ software to 
determine the amount of white space relative to total kidney area. Manual 
determination of inclusive areas was used to exclude artifacts from section 
preparation (i.e. holes, debris, etc.). Each sample was measured three times with 
the average used for analysis. 
Crystal Aggregate Analysis 
Crystal aggregates were counted and scored using ImageJ software. 7-10 fields 
from 20x images were obtained from both cortical and medulla areas of kidney 
sections from treated animals before being analyzed. Aggregates were determined 
to be clusters of crystals within a single tubule.  
  38 
Polarizing Microscopy 
Polarizing microscopy was used with H & E prepared tissue sections to observe 
the presence of birefringent oxalate crystals. 
Cell Height, Tubule and Lumen Diameter 
Tubule diameter was measured from the basal membrane across the narrowest 
segment of the tubule to the basal membrane of the opposite side of the tubule. 
Lumen diameter was determined by measuring the brush border to the brush 
border of the narrowest portion of the tubule. Cell height was determined by 
measuring three cells per dilated tubule, measuring the cell height from the basal 
to apical membrane across a cell nucleus. The researcher performing the 
measurements was blinded to the treatments. 
Western Blotting 
Sample Preparation-Tissues were removed from animals, bisected sagittally, and 
placed into a mortar cooled with liquid nitrogen, submersed in liquid nitrogen and 
pulverized using a pestle. These samples were then placed into microcentrifuge 
tubes and stored at -80˚C for future analysis. Approximately 10mg of tissue were 
lysed in 200µL of 4% SDS-100mM Tris pH 6.8 lysis buffer containing 
phosphatase and protease inhibitors (Phosphatase inhibitor cocktail 2 & 3 (Sigma-
Aldrich), PMSF, Protease Inhibitor cocktail (Sigma-Aldrich)). These samples 
were then extensively vortexed and heated at 100˚C for 10 minutes followed by 
extensive vortexing. The samples were then centrifugated at 13g for 10 minutes to 
pellet non-soluble cell debris. The supernatant was then transferred to a new 
microcentrifuge tube and protein concentrations were determined using a 
NanoDrop spectrometer reading absorbance at 280nm. 
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SDS-PAGE and Antibodies-Bromophenol blue and 50mM DTT were added to 
protein samples in 2% SDS-50mM Tris pH 6.8 buffer prior to being heated at 
100˚C for 5mins to reduce disulfide bonds. Samples were then loaded at standard 
concentrations of 50µg per well using 10% acrylamide gels for SDS-PAGE. The 
gels were run for approximately 90mins at 100V followed by transfer onto 
nitrocellulose membranes at 100V for 90mins in an ice bath. The membranes were 
blocked using 5% BSA-TBST for 20mins at 37˚C followed by 3, 5min rinses in 
TBST. The membranes were then incubated overnight at 4˚C on a rotator in 
primary antibody solutions containing 5% BSA-TBST (Mouse anti-Actin, 
Amershan Bioscience N350; Rabbit anti-pS6S235/236, Cell Signaling #4858; Rabbit 
anti-total-S6 Cell Signaling #2217; Rabbit anti-Src, Cell Signaling #2109; Rabbit 
anti-pSrcY416 #6943; Rabbit anti-pSTAT3Y705, Cell Signaling #9145; Mouse anti-
STAT3, Cell Signaling #9139). The following day the membranes were washed 3 
times for 5 minutes in TBST and incubated in the appropriate species specific 
fluorescent or HRP conjugated secondary antibodies (Goat anti-mouse-IR Dye 
800CW, Li-Cor #926-32210; Donkey anti-rabbit-IR Dye 680, Li-Cor #926-32221, 
Goat anti-rabbit HRP, Jackson ImmunoResearch #111-035-144, Goat anti-mouse 
HRP, Jackson ImmunoResearch #115-035-044) in 5% Dry Milk-TBST for 
45mins at 25˚C under agitation while preventing exposure to external light 
sources. The membranes were then rinsed in TBST for 15mins before 
visualization using chemiluminescence (Pierce) or LiCor scanner.  
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TUNEL Assay 
Apoptosis was measured by TUNEL assay (Click-iT® Plus, cat. No. C10617, 
Thermo Fisher Scientific). Apoptotic nuclei and DAPI positive cells per field 
were counted.  
Statistical Analysis 
Data sets were tested for normality prior to a nonparametric, one tailed, Mann-
Whitney analysis with Prism graphing software. All graphs display the standard 
deviation. Box whisker plots represent 90% of values with median displayed as a 
line in between the 2nd and 3rd quartiles and the mean displayed with “+”. 
Variances between statistically compared groups differed.  
Human PH Samples 
Human primary hyperoxaluric samples (n=3) were donated from Dr. Bernd Hoppe 
from Universitätsklinikumbonn Germany.  
Data Availability 
Data requests are available from the corresponding author. 
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III.  
The Soluble C-terminal Tail of Polycystin-1 Interacts with mTOR, 
Mitochondrial Associated Proteins, and Protects Against Calcium 
Induced Cytotoxicity 
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Abstract  
 Polycystin-1 (PC1) is the primary protein associated with the initiation of 
ADPKD, accounting for 85% of the cases reported. PC1 is a large multi-pass 
integral membrane protein that contains a 200-amino acid C-terminal 
cytoplasmic tail. Under certain cellular conditions, the cytoplasmic tail of PC1 
may undergo proteolytic cleavage to produce a soluble 30kDa fragment (p30). 
The p30 fragment may then undergo translocation to the nucleus and coactivate 
STAT3 mediated gene transcription30. It has been observed that the cyst lining 
epithelia cells in ADPKD kidneys exhibit increased levels of the cytoplasmic 
PC1 tail within the nucleus106 and increased levels of active STAT3 (Fig. 8). We 
therefore hypothesized that the small p30 fragment may be a critical regulator in 
the initiation and maintenance of ADPKD. Here I show that p30 interacts with 
the primary target of rapamycin, mTOR, a critical regulator of cell growth, and 
proliferation in ADPKD and additionally associates with the mitochondrial 
proteins AIF and the ATP synthase β-subunit. Drug treatment with the ionophore, 
ionomycin and p30 expressed in MDCK cells showed resistance to calcium 
induced cytotoxicity. Taken together, these data show p30 involvement in mTOR 
signaling, oxidative phosphorylation, programmed cell death and the protective 
effects observed from ionomycin induced calcium cytotoxicity.  
 
 
 
  43 
A. Introduction 
The cytoplasmic tail of polycystin-1 contains a 200 amino acid intracellular 
domain that can be cleaved by γ-secretase107 at the membrane to form a soluble 
30kDa fragment (p30/FLS). This terminal p30 fragment appears to be an 
important region for protein interactions and signaling. The structure of the tail is 
predicted to be a coiled-coil domain containing a cleavage site for Caspase-122, a 
PEST domain, a calmodulin binding domain108 and has been shown to bind to 
multiple proteins that are involved with DNA repair, energy metabolism  and 
apoptosis (Fig. 10). Following cleavage by Caspase-1, the p30 fragment is split 
into a smaller active fragment, p15, that also appears to have biological activity22.  
The increase in STAT3 activity is believed to be part of the mechanism for 
cyst formation and may be exacerbated by aberrant coactivation of p30.  
Following injury, PC1 is cleaved at the membrane to release the soluble p30 
fragment whereby it translocates to the nucleus and coactivates STAT3 gene 
transcription. The cleavage and translocation of p30 has been observed in 
unilateral ureteral obstructed mouse kindeys106. This translocation into the nucleus 
can be mediated by expression of PC2 and the activity of p30 appears to require 
its nuclear localization to mediate gene transcription106.  
The small soluble p30 fragment has been shown by our lab to coactivate 
STAT3 gene transcription via a dual mechanism6. This dual activity of p30 occurs 
from its ability to increase STAT3 gene transcription via the activation of Src or 
Janus kinase (JAK) activity (Fig. 9). The IL-6 receptor mediates the activation of 
JAK signaling whereas increases in c-AMP or extracellular growth factors activate 
Src. Paradoxically, upregulation of suppressor of cytokine signaling 3 (SOCS3) 
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and STAT3 activation are both observed in human ADPKD cyst lining epithelia 
cells30. Increased levels of cytokines and growth factors are also observed within 
cyst fluid31 which may be the cause of activation. In ADPKD, the activation of 
STAT3 is accompanied by an increase in SOCS3, implying that the activation of 
STAT3 is occurring from an alternative pathway mediated by Src.  
 
Figure 9: Proposed signaling mechanism involving the p30 fragment of polycystin-1: p30 can 
coactivate STAT3 gene transcription through its ability to directly increase STAT3 activity, or by 
increasing the activity of Src which in turn phosphorylates STAT3. STAT3 can be phosphorylated 
via the IL6/JAK pathways or through the activation of Src through increases in cAMP and PKA, or 
EGFR phosphorylation. 
 
 STAT3 phosphorylation can occur from the IL-6 Receptor/GP130 
activation JAK, and alternatively by EGF receptor or vasopressin receptor 
activation of Src. The activation of the EGF receptor directly activates Src through 
its tyrosine kinase activity and activation via vasopressin leads to an increase in 
intracellular cyclic AMP and Src activity through protein kinase A (Fig. 9). 
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Research on the vasopressin receptor antagonist Tolvaptan has shown moderate 
success in ameliorating PKD in human patients, but with side effects that make 
compliance challenging. Reduction of cysts in response to vasopressin antagonism 
and high levels of cAMP in cyst fluid implicates the activation of Src via PKA.  
In addition to the regulation of STAT3, the C-terminal tail of PC1 has been 
shown to be directly involved in the negative regulation of mTOR signaling by its 
interaction with the Tuberous Sclerosis protein Tuberin (TSC2)29. When the PC1 
tail is tethered to the membrane it is capable of repressing mTOR activation by 
keeping TSC2 sequestered at the membrane. This fits with the observation of 
increased mTOR activity in ADPKD cyst lining cells and the increase in PC1 C-
terminal cleavage following injury106.  
The activation of p30 in response to injury in is believed to be a normal 
response for the cell in initiation of the repair response. In ADPKD, cystic cells 
are unable to cease the cycle of PC1 cleavage, mitogenic signaling, and p30 
coactivation of STAT3. This cycle of activation by p30 we believe is involved in a 
futile repair response, resulting an excessive proliferation following injury.  
The dysregulation of mTOR signaling appears to underlie the pathology of 
ADPKD. I investigated if there is a direct physical interaction between the C-
terminal tail of polycystin-1 and mTOR. The Tuberous Sclerosis complex (TSC) 
comprised of Hamartin/Tuberin (TSC1/TSC2) proteins negatively regulates 
mTOR. The function of TSC2 is to activate the G-protein Rheb that in turn 
activates mTOR complex 1 (mTORC1). When TSC2 is bound to the membrane 
tethered TSC1, the TSC is formed and TSC2 is sequestered on the plasma 
membrane in its inactive form and the activity of mTORC1 is inhibited.   
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B. Results 
p30 and mTOR 
To test if there is an interaction between the C-terminal tail of PC1 and 
mTOR, tagged versions of both p30 and mTOR were used. HEK293t cells were 
transfected with membrane bound p30 (“Full Length Soluble Membrane Bound” 
or FLM) and the soluble tail of PC1 (“Full Length Soluble Fragment” or 
FLS/p30), followed by affinity chromatography and immunoblotting (Fig. 10).   
 
Figure 10: Interaction between the C-terminus of PC1 and TSC2: HEK293t 
cells cotransfected with TSC2 and GST tagged FLS/p30 (FLS-GST) or GST 
tagged membrane bound FLS/p30 (FLM-GST). Both GST-FLM and GST-FLS 
bound to TSC2 with the soluble form of FLS showing a higher affinity. “Input” 
samples are whole cell lysates used for the experiment. “After” samples represent 
depleted samples following GST pull down.  
 
When TSC2 was cotransfected with the soluble tail of PC1 (FLS-GST), 
there was an increase in the amount of protein bound to the beads relative to the 
membrane tethered version of the PC1 tail (FLM-GST). This direct interaction 
between the C-terminus of  PC1 and TSC2 has also been investigated by Dere et 
al and shown to inhibit mTORC1 signaling29.  After verifying that there was an 
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interaction between p30 and the mTOR regulator TSC2, I next investigated the 
possibility that mTOR interacts with p30. HEK293t cells were transfected with 
mTOR and either soluble or membrane bound p30 (Fig. 11). 
 
Figure 11: Interaction between of a soluble or membrane bound form of the 
PC1 c-terminal tail in CHAPS buffer: HEK293t cells cotransfected with mTOR 
and GST tagged FLS/p30 (FLS-GST) or GST tagged membrane bound FLS/p30 
(FLM-GST). mTOR bound with the soluble form of FLS and not membrane 
bound. “Input” samples are whole cell lysates used for the experiment. “After” 
samples represent depleted samples following coimmunoprecipitation. 
 
A strong interaction with mTOR was observed with the soluble fragment 
but no interaction was observed with the membrane bound p30. Attempts to 
isolate the mTOR/p30 interaction using standard coimmunoprecipitation buffers 
containing Triton detergent were unsuccessful. Using CHAPS buffer allowed for 
detection of mTOR with p30, presumably this is because mTOR’s interaction with 
p30 is through another protein interaction complexed with mTOR that is disrupted 
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by more harsh detergents. I next tested where the binding of mTOR to p30 may be 
occurring. Cotransfection of mTOR with two C-terminal deletion constructs of 
p30 (amino acids 4107-4272 (165AAs) and 4107- 4195 (88AAs) of PC1) showed 
that the binding of mTOR to p30 is inhibited nearly equally following the 
truncation of the last 41 residues of the C-terminus (Fig. 12).  
These data show that PC1 may be directly involved in the regulation of 
mTOR through binding of the PC1 C-terminus to both TSC2 and mTOR, either as 
part of a complex or direct interaction. Because this is an overexpression model, 
more investigation into the function of this interaction will be necessary to 
determine if this interaction does in fact regulate mTOR signaling. 
This experiment places mitochondria front and center in PKD as more evidence 
mounts to implicate glucose necessity and defective cellular metabolism as a 
hallmark of PKD.   
 As a first step in investigating the implication for mitochondrial 
involvement in ADPKD, we performed a mass spectrometry screen following 
GST pull-down of the p30 fragment in transfected HEK293t cells. We compared 
these results to GST alone transfected cells. Of the numerous mass spectrometry 
hits we received in the screen, two mitochondrial proteins appeared that were of 
particular interest, the ATP synthase β-subunit and apoptosis inducing factor 
(AIF). 
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Figure 12: Interaction mapping between the C-terminus of PC1 and mTOR: 
HEK293t cells cotransfected with mTOR and GST tagged FLS/p30 (FLS-GST) 
truncation mutants of the C-terminus of FLS. mTOR binding was inhibited by 
deletion of the last 41 residues of FLS. Input=whole cell lysates 
 
 ATP Synthase β-Subunit 
 Following the mass spectrometry pull-down, I wanted to confirm the mass 
spectrometry interaction data via western blot. The ATP synthase β-subunit was 
intriguing because the interaction between the homolog of PC1, LOV-1 had been 
previously reported in C. elegans109. Hu et al reported that LOV-1 and the ATP 
synthase β-subunit were required for normal mating behavior with the interaction 
observed only in sensory neurons. This interaction was observed in a yeast to 
hybrid screen with the interaction in the PLAT domain of LOV-1, not the C-
terminal tail and not in mitochondria. The PLAT domain is the most conserved 
region of PC1 and located 1000 amino acids away (AA 3107) from the C-
terminus. The PLAT domain is associated with the membrane bound portion of 
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PC1 on the cytoplasmic side of the N-terminal GPI cleavage site.  This may imply 
that the interaction with the ATPase may be used in regulating proton movement 
at the plasma membrane or an as yet unknown function of PC1.  
HEK293t cells were transfected with p30 (FLS-GST) and probed for the 
ATP synthase β-subunit. Our lab has shown that the p30 fragment can be 
stabilized by inhibition of prolyl hydroxylase using either cobalt chloride or 
mimosine (unpublished). GST pull down revealed that binding to p30 was 
occurring to the ATP synthase β-subunit but was unaffected by treatment with 
cobalt chloride or mimosine (Fig. 13). I did not observe a stabilization of p30 as 
expected which may have been due to the fact this was an overexpression from 
transfection which may already be maximally expressing p30 and no further 
increase in protein is detectable. More experiments will need to be performed to 
verify this result and to test for a possible effect of this interaction.  
 
Figure 13: FLS Interacts with the ATP synthase β-subunit and Apoptosis 
Inducing Factor: HEK293t cells transfected with FLS-GST (p30) and subjected 
to GST pull-down following by immunoblotting of AIF and ATP synthase β-
subunit wither with or without mimosine or cobalt chloride treatment. Input 
represents whole cell lysates, “After” represents depleted samples and “Pellet” 
represents all cellular fractions separated during centrifugation prior to GST pull 
down. 
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 Apoptosis Inducing Factor 
The other interesting mitochondrial protein obtained from the mass spec 
screen that showed a much stronger affinity for p30 (Fig.13) was AIF. AIF is 
localized to the inner mitochondrial membrane and is involved in caspase 
independent programmed cell death110. AIF is a Janus protein possessing FAD 
redox potential. AIF is tethered to the inner mitochondrial membrane by a 
proteolytically sensitive linker domain, sensitive to both calpain and cathepsin 
proteolysis. Cleavage of AIF can be caused by cellular insult from increases in 
calcium, ROS and DNA alkylating agents111. Following cleavage, AIF leaves the 
mitochondrion and translocates to the nucleus where it catalyzes chromatin 
condensation. While AIF does not possess endonuclease activity, its presence in 
the nucleus appears necessary for chromatin condensation111.  AIF is translated as 
a 67kD pro-protein with an N-terminal mitochondrial localization sequence. 
Following translocation to the mitochondria, AIF is cleaved into the mature form 
with an apparent weight of 62kD. The N-terminal portion of the protein faces the 
mitochondrial matrix and the C-terminus faces the intermembrane space112. The 
N-terminal portion contains both FAD and NADH binding domains. AIF also 
exhibits oxydoreductase activity and is capable of reducing cytochrome C111. The 
function of AIF appears to be involved in regulation of complex 1 activity of the 
electron transport by regulation of ROS production113. Paradoxically, knockdown 
of AIF results in a 1.5-2 fold increase in ROS production in Hela cells and a 
decrease in in ROS activity in 5 other cell lines tested113. The difference may be 
explained by AIF modulation of complex 1 activity. AIF’s role may be to regulate 
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the oxidation of complex 1 in response to ROS production, increasing activity by 
decreasing oxidation.   
The association of a protein like AIF with the C-terminal tail of PC1 begs 
speculation about what the possible role of this interaction might be. In the 
immunoprecipitation assay (Fig. 13), the p30 fragment appears to associate 
strongly with AIF an enriched band that is of a slightly higher molecular weight 
than the band observed in the input samples. This may imply that the association 
of p30 and AIF is occurring in the cytoplasm or prior to the insertion of AIF into 
the mitochondrial inner membrane. This is an important distinction as the 
association of full length PC1 and the mitochondria has not been observed. 
However, our lab has observed that the p30 fragment appears to associate with 
structures that appear to be mitochondria under hypoxic conditions.  
Recently the link between PC1 oxygen sensitivity and the mitochondria 
has been investigated. The association of PC1/PC2 in the ER and near the 
mitochondria is believed to be regulating calcium release from the ER for use in 
the mitochondria114. This is in conjunction with the prolyl hydroxylase EGLN3 
that associates with the C-terminal tail of PC1 and regulates its trafficking to the 
plasma membrane under hypoxic conditions. Our lab has observed that prolyl 
hydroxylation is necessary for the regulation and degradation of the p30 fragment 
via the proteosome. It may be that the function of PC1 is to regulate the activity of 
the mitochondria via calcium regulation under normoxic conditions and then to 
prevent excessive ROS damage under hypoxic conditions. The association of PC1 
and with the preprocessed form of AIF may serve as a regulation step for complex 
1 activity.   
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  Cell Death and Metabolism 
After the confirmation between the association of p30 and AIF, I next 
checked if there was a cell death phenotype associated with p30 expression. To 
test this effect, an inducible MDCK cell line that expresses p30 following 
doxycycline administration. Using Alamar blue as a readout for cell death, I 
assayed for calcium induced cytotoxicity following ionomycin treatment. 
Comparing cell death at 24 hours under varying ionomycin concentration gave a 
dose of 500nM as an effective dose for killing cells (Fig. 14).  
 
Figure 14: Alamar blue assay of ionomycin treated MDCK-FLS cells: MDCK 
cells stably expressing a doxycycline inducible version of p30 were exposed to 
varying concentrations of ionomycin 24 hours post ionomycin treatment to test for 
the effects on cell death. 
 
The assay also revealed what appeared to be a possible increased effect on 
cell death from ionomycin in p30 expressing cells. To verify if there was an effect 
on cell death from p30 expression, I utilized another cell death assay that measures 
the amount of lactate dehydrogenase (LDH) released in the media from apoptotic 
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cells. LDH is normally an intracellular protein and should therefore not be in the 
media unless it is released from detached cells presumed to be apoptotic. 
The LDH release assay revealed that there was a reduction in the amount 
of cell death observed in cells expressing p30 (Fig. 15), contradictory from the 
Alamar blue assay. The difference in outcomes is likely attributed to the difference 
in the way the assays measure cell death. The Alamar blue assay measures the 
reducing potential of the cells in culture to equate live cell activity. This 
measurement can be skewed if there is an effect in the cell that is altering cellular 
metabolism or redox reactions. If p30 is regulating a decrease in cellular 
metabolism in response to increased levels of calcium, it would be seen as a 
decrease in cell count via Alamar blue. The LDH release assay only measures the 
LDH that is released from cells that are apoptotic. Therefore, the LDH assay is a 
more reliable assay in terms of cell death and was used to measure the effects of 
ionomycin over time. 
 
Figure 15: LDH release following ionomycin treatment in MDCK-FLS cells: 
MDCK cells stably expressing a doxycycline inducible version of p30 were 
exposed to varying concentrations of ionomycin 24 hours post ionomycin 
treatment.  
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Figure 16: LDH release over time from ionomycin treated MDCK-FLS cells: 
MDCK cells stably expressing a doxycycline inducible version of p30 were 
exposed to 500nM ionomycin and assayed up to 24 hours post ionomycin 
treatment. 
 
Taken together, these data imply that p30 may be involved in a yet 
unrecognized mechanism to regulate cellular metabolism and apoptosis following 
calcium toxicity. While it is not clear in what way this mechanism is taking place, 
it does look like p30 can protect against calcium induced cell death by regulating 
the cell’s redox potential which may be to reduce toxic damage from reactive 
oxygen species. I next treated cells with 500nM ionomycin and measured the LDH 
release over time (Fig. 16). There was a marked effect in the amount of cell death 
measured after one hour and cells appeared to be resistant to cell death even after 
four hours of ionomycin treatment. These data suggest that p30 serves in a 
protective mechanism in calcium induced cytotoxicity possibly by regulating 
redox potential.  
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C. Discussion 
The cytoplasmic tail of polycystin-1 appears to be quite promiscuous, involved 
in regulation of intracellular and mitochondrial calcium levels114, gene 
coactivation30, mTOR activity29, and possible direct regulation of mitochondrial 
function. I have presented some interesting data and leads to follow. Of interest 
are the interactions between p30, mTOR and AIF.  It would be worth to 
investigate if the interaction between mTOR and p30 is through a direct 
interaction or through a complex, if that interaction is preserved with the full-
length PC1 protein, and if it serves any function.  
The p30/AIF interactions beg speculation as AIF is directly involved in non-
caspase mediated cell death and is activated by increased levels of intracellular 
calcium, and is involved in electron transport regulation. PC1 regulation by 
EGLN3 during hypoxia114  make PC1 an oxygen sensor capable of regulating  
mitochondrial calcium levels by interacting with PC2 at the ER. This regulation of 
oxidative phosphorylation may also be as a direct regulator through complex 1 
and/or 4 of the electron transport under hypoxic conditions by p30 interaction with 
AIF and the ATP synthase.   
The C-terminal of PC1 binds with PC2 to form a calcium channel at the ER 
capable of regulating mitochondrial calcium levels and intracellular levels at the 
primary cilium by sensing fluid flow. Cleavage of the PC1 tail would presumably 
prevent the influx of calcium through PC1/2 disassociation. p30 cleavage is shown 
to occur in response to cessation of fluid flow from a lack of cilia bending. This 
could potentially result in a potentially hypoxic state as tubule obstruction can lead 
to decreased levels of oxygen. Association of p30 with the pro-form of AIF, prior 
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to its insertion into the mitochondrial membrane could prevent an increase in 
mitochondrial oxidative phosphorylation by disrupting membrane incorporation of 
AIF. This may make the C-terminal tail a signal for cellular oxygen status by 
integrating extracellular signals to the mitochondrial using AIF regulation.  
The protective affect against ionomycin induced cytotoxicity may mean that 
p30 is regulating the effect of AIF induced cell death rather than its role in the 
electron transport chain. This effect may also be through electron transport 
regulation, preventing cellular damage. The location of the p30/AIF interaction 
needs to be determined first to make assumptions about possible functions.  
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IV.  
The Ketogenic Diet as a Treatment for Autosomal 
Dominant Polycystic Kidney Disease 
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Abstract 
The ketogenic diet has been shown effective in treating a number of 
metabolic and inflammatory diseases115,116. Ketosis causes the production of the 
ketone body β-hydroxybutyrate (βHB), a powerful signaling molecule, as a 
product of fatty acid metabolism. A ketogenic diet could counteract several 
important molecular targets in ADPKD as βHB has been shown to inhibit the 
activity of mTORC1117, increase AMPK activation, is a known histone 
deacetylase (HDAC) inhibitor118 and provides substrate for mitochondrial aerobic 
respiration32. ADPKD cysts show defects in aerobic fat metabolism with a 
concomitant shift to aerobic glycolysis32, similar to a cancer cell’s Warburg effect. 
mTORC1 is known to be upregulated in ADPKD and the mTOR inhibitor 
rapamycin has proven an effective treatment for ADPKD in rodent models7,8. 
Similarly, the use of HDAC inhibitors have shown promise in treating ADPKD119 
along with inhibition of aerobic glycolysis utilizing 2-deoxyglucose32. Taken 
together, the ketogenic diet may be a possible alternative to drug therapy for the 
treatment of ADPKD by decreasing overactive mTOR signaling and repairing the 
metabolic disease state in ADPKD.   
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A. Introduction 
 
Figure 17: Pathways in ADPKD potentially affected by β-hydroxybutyrate: 
ADPKD pathways that are potentially affected by an increase in β-
hydroxybutyrate.  
 
 
Endogenous production of βHB occurs when employing a ketogenic diet and 
has already shown promise for the treatment of a number of metabolic and 
inflammatory diseases115,120,121. ADPKD exhibits several characteristics of 
metabolic and inflammatory diseases that make it an excellent candidate for 
treatment with a ketogenic diet. ADPKD patients are known to exhibit higher 
incidences of diabetes. Additionally, it has been shown that hyperglycemia is 
capable of exacerbating PKD following cilia ablation in the IFT88 knockout 
mouse122. The use of animal models to study ketosis has been well established 
utilizing supplementation with ketone esters123, βHB salts124, medium chain 
triglycerides124, and macronutrient manipulation121,124. Ketosis has been utilized as 
a treatment for epilepsy120,  has been demonstrated to be safe and effective at 
treating inoperable tumors116 and is currently being investigated for 
neurodegenerative diseases like Alzheimer’s125. Taken together, the ketogenic diet 
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gives us an effective tool to begin studying the effects of ketosis on ADPKD 
progression.  
Our lab recently published work demonstrating that caloric restriction is 
capable of ameliorating the cystic phenotype in mice with ADPKD105.  The effects 
of caloric restriction on ADPKD may be due to several factors that come from the 
decrease in caloric intake. A decrease in caloric load leads to a state of ketosis, in 
which the body utilizes fat primarily for energy. The production of ketone bodies 
during times of caloric restriction not only provide energy, but also serve as potent 
signaling molecules for a number of pathways associated with ADPKD5,9,14,15,16. 
Ketogenesis produces three distinct ketone bodies: β-hydroxybutyrate, acetone and 
acetoacetate that each serves unique functions. Utilization of ketone bodies has 
been shown to boost expression of hypoxia inducing factor 1-alpha (HIF-1) 
through an inhibition of prolyl hydroxylase activity, putatively via an increase in 
succinate126. βHB administration can act as a histone deacetylase class 1 and 2a 
inhibitor127 while concomitantly activating Sirt1 acetylase activity126 (Fig. 17). 
Ketosis also produces a more efficient use of oxygen and in animals is coupled to 
an increase in superoxide dismutase, catalase alongside a decrease in 
inflammasome markers of stress via AMPK activation128. Additionally, an 
increase in ketone bodies is shown to decrease mTORC1 activity while regulating 
an increase in macroautophagy and mitochondrial biogenesis126,129. Each of these 
pathways affected by ketosis has been targeted for therapeutic intervention in the 
treatment of ADPKD. Taken together, these data support the use of ketone bodies 
and the ketogenic diet as a potential alternative and effective treatment for 
ADPKD.  
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B. Results 
 To test the effect of the ketogenic diet on the progression of PKD, wild-
type and PKD male and female Han:SPRD rats were treated for 5 weeks on a 
high-fat ketogenic diet beginning at 3 weeks of age. All the ketogenic diet treated 
animals were given ad libidum access to a high fat paste consisting of corn oil, 
lard, casein and dextrose with a caloric ratio of 75% fat to 8% protein and 13% 
carbohydrates. This diet is contrasted and compared to the normal chow fed 
animals consisting of 60% calories from carbohydrates, 25% from protein and 
15% from fat. The caloric ratios given to the ketogenic animals mimic those of 
humans practicing a ketogenic diet but with a further reduced protein 
consumption. 
Upon examination of the kidneys, there was a marked decrease in the 
appearance of cysts in the ketogenic diet treated animals relative to the control 
normal chow fed animals (Fig. 18). There also appeared to be a decrease in the 
size of cysts observed by H and E. There was also a decrease in the overall kidney 
size that was commensurate with the wild-type controls. At the end of the 5-week 
study there was a significant reduction in the 2-kidney to bodyweight ratio in both 
male and females on the ketogenic diet in comparison to their normal chow 
controls (Fig. 19).  The reduction in 2-kidney to body weight was relative to the 
normal chow fed controls in the wild-type and PKD animals. This indicates that 
the reduction in the 2-kidney to bodyweight ratio in PKD animals is not due solely 
to an overall reduction in total organ growth per se. It should be noted that there 
was a dramatic reduction in the size of the animals following the 5-week period on 
the ketogenic diet relative to the normal chow fed controls (Fig. 20A).  
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Figure 18: Hematoxylin and Eosin stain of ketogenic and normal chow Han 
rats: 8-week-old polycystic and wild-type Han:SPRD male and female rats fed on 
either normal chow or a ketogenic diet.  
 
 
 
Figure 19: Two-kidney to bodyweight ratios of ketogenic and normal chow 
fed rats: 2-Kindey to bodyweight ratios of wild-type and polycystic Han rats 
treated with normal chow or a ketogenic diet.  
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Figure 20: Mass and β-hydroxybutyrate measurements of ketogenic and 
normal chow Han rats over time: A.) Mass of wild-type and PKD male and 
female Han rats treated on the ketogenic diet or normal chow. B.) β-HOB levels of 
male and female wild-type and PKD Han rats.   
  
 Lack of tissue glycogen and the accompanied loss of associated water in 
addition to the decrease in protein are the most likely causes of the decreased mass 
of the animals treated with the ketogenic diet. As expected, there was an increase 
in βHB levels in the animals on a ketogenic diet relative to normal chow fed 
animals (Fig.20B).  
When examining the individual animals over the course of the study, 
ketogenic treated animals increased by approximately 10%-15% in mass over the 
course of the study (Fig. 21A).  This is contrasted to a more than doubling of the 
animals on normal chow diet in (Fig. 20A). This lack of growth is most likely due 
to the low protein content of the ketogenic formulation, making a consideration 
for a future study to optimize the protein content of the diet. Other than a decrease 
in the rats overall size, the ketogenic treated animals all appeared to be active and 
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in good health. All the animals on the ketogenic diet showed an increase in βHB 
levels over the 5-week period (Fig. 21B). Alongside the increase in βHB, there 
was a concomitant decrease in blood glucose levels observed in all animals (Fig. 
21C). 
 To assess the function of the kidneys, blood urea nitrogen (BUN) levels 
were assayed in ketogenic and normal chow fed rats (Fig. 22). There was a marked 
reduction in all the ketogenic animal’s BUN values compared to the normal chow 
fed controls. This decrease in BUN was observed in both the wild-type and the 
polycystic rats to a similar extent indicating that the effect of genotype was not as 
prominent as the effect of the ketogenic diet itself. Again, this decrease in BUN 
may be a cause of the low protein content rather than an effect of the diet per se. It 
is worth to note that this decrease in BUN may still offer palliative benefits by 
decreasing the filtration work output of the kidney.  
To elucidate the signaling pathways that may affect cystic disease 
progression (Fig. 17), we analyzed signaling pathways identified in PKD (Fig. 23). 
There was a modest decrease in phospho-S6S233/234 in ketogenic treated wild-type 
and PKD male rats.  Unexpectedly, this is contrasted by an increase in phospho-
S6S233/234 observed in female PKD rats fed a ketogenic diet but does not appear to 
result in an increase in active phospho-4E-BP1. No change was observed in 
phospho-S6S240/245. An increase in phospho-AMPKT172 was observed in all 
ketogenic treated animals relative to the normal fed chow PKD and wild-type rats. 
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Figure 21: Weekly measurements of a single cohort of animals treated on the 
ketogenic diet: Rats were measured for A.) Mass, B.) β-hydroxybutyrate and C.) 
Blood glucose.  
 
 
 
Figure 22: BUN levels of ketogenic and normal chow fed Han rats over time: 
BUN levels of PKD and wild-type rats on a ketogenic diet or normal chow. 
(**=P>0.01) 
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Figure 23: Western blot for ADPKD associated pathways in ketogenic and 
normal chow Han rat kidneys: 8-week old Han rat kidney lysates were probed 
for total and phosphorylated-S6S233/234&S240/245, total and phosphorylated-
AMPKT172, total and phosphorylated-STAT3Y705, LC3, phosphorylated-AktS473 
and phosphorylated-4E-BP1. Actin was used as a loading control.  
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 Another unexpected result was the increase in phospho-STAT3Y705 in the 
male and female ketogenic treated animals. Previously, our lab has used the 
appearance STAT3 as a marker of PKD and has been observed in models of PKD 
in the cyst lining epithelia. It is therefore difficult to speculate on the source or 
function of this increase. We examined the marker of autophagic flux, LC3, to 
assess if the lack of animal growth and the induction of ketosis coincided with an 
increase in autophagy. It appears that there is a difference between male and 
female rats in the active LC32 and pre-autophagic LC31 proteins. Male PKD rats 
appear to have more LC31 protein whereas females express more of the active 
LC32 form. In the ketogenic animals, there does appear to be an increase in the 
overall levels of LC1 levels relative to wild-types, with female PKD rats showing 
an increase in LC32. Phosphorylation of S473 of Akt is associated with mTORC2 
activity130 indicating that the ketogenic diet appears to increase mTORC2 activity 
in both males and females.  
 The changes in signaling for animals on the ketogenic diet showed some 
expected changes with an increase in mTORC2 and AMPK. Unexpectedly, there 
were differences in males and females on a ketogenic diet. This sex specific 
difference will require exploring further.  
C. Discussion 
 The ketogenic diet has grown from being used for the treatment of 
epilepsy, to currently being researched for the treatment of neurodegenerative and 
metabolic disorders125,131. The renewed interest in ketosis has sparked =because of 
the powerful effects on cellular signaling and metabolism that can be elicited from 
the ketogenic state. The profound effects of the diet are linked primarily to the 
  69 
production of the ketone body, β-hydroxybutyrate (βHB). βHB has been shown to 
play a central role in the effects observed while in ketosis, serving as a substrate 
for mitochondrial aerobic oxidation and as a transcriptional regulator117. Amongst 
the regulatory effects of βHB is its ability to inhibit mTORC1 via AMPK 
activation. AMPK is downregulated in PKD along with a concomitant increase in 
mTORC1 activity. mTOR inhibitors have shown therapeutic potential in rodent 
models of ADPKD but have not fared well in human trials. Since βHB is 
produced endogenously in the ketogenic state, this makes βHB an appealing 
alternative for ADPKD treatment over mTOR inhibitors.  
 In the current study, there was a nearly 20-fold increase in the levels of 
βHB for animals on a ketogenic diet at the end of the 5-week period (Fig. 20). 
This was accompanied by an expected increase in phosphorylated AMPK for all 
animals in ketosis. The increase in AMPK activation paradoxically was 
accompanied by an apparent increase in mTORC1 and mTORC2 signaling. 
AMPK is responsible for inhibition of mTORC1 through the phosphorylation of 
Raptor, the binding partner of mTOR necessary for complex 1 formation, 
phosphorylation of Raptor prevents complex 1 assembly. AMPK also targets the 
upstream regulator of mTORC1 activation, TSC2, which subsequently inhibits the 
GTPase Rheb, additionally disrupting the assembly of the mTORC1 complex132. 
Activation of 4E-BP1 by phosphorylation is a direct downstream target of 
mTORC1 and showed an increase in ketogenic diet male rats (Bottom Fig. 23). 
This was accompanied with an increase of AktS473 phosphorylation, a marker for 
mTORC2 activity (Fig. 23). The increase in both mTORC1and mTORC2 activity 
appears to conflict as each complex act as a negative regulator of the other.  
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 Explanation for the simultaneous activity of mTORC1/2 may be the 
upstream regulation of PTEN by the Hippo pathway. The Hippo pathway is 
involved in the regulation of organ size by controlling apoptosis and proliferation. 
Extracellular growth signals integrate and stabilize the transcription factor, Yes-
Associated Protein (YAP). YAP is responsible for the transcription of miR-29, a 
negative regulator of PTEN translation. Decreased PTEN activity leads to an 
increase of PtdIns(3,4,5)P3 via PI3K133, which, in turn will lead to an activation of 
both the mTOR 1 and 2 complexes. This would match the observation of a 
decrease in autophagy, an increase in phosphorylated 4E-BP1, and the increase in 
AktS473 phosphorylation.  
 The activity of Hippo would indicate that the signal for growth is in place 
without the needed substrate to proceed. The lack of growth in the animals may be 
entirely due to a lack of necessary nutrients to proliferate new cells. A lack of 
amino acids may impair the increase in animal size. Hippo has been shown to be 
dysregulated in Pkd1 null cyst epithelial cells by mislocalization of YAP and 
altered levels of downstream effectors134. Future experiments might include 
additional protein sources to overcome this growth deficiency by providing more 
substrate for protein synthesis in the form of essential amino acids. An increase in 
the cystic phenotype under these circumstances may implicate the role of the 
Hippo pathway as a direct regulator of cystogenesis in the Han rat. Despite the 
lack of growth, there was an observable decrease in cysts in the kidneys of PKD 
animals on the ketogenic diet and is worth further investigation. 
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V.  
Future Directions and Conclusions  
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In summary, I have presented several novel findings. First is the finding that 
crystals can exacerbate cystogenesis in a rat model of ADPKD and demonstrates 
that there is an endogenous trigger for cystogenesis (Chapter II). This is a critical 
discovery in the PKD field and shifts the emphasis away from researching drug 
targets and towards a possible therapeutic intervention that involves dietary 
modification. The field has come a long way in elucidating the function of the 
polycystins, cilia and the role they play in cyst formation. Second, I was able to 
demonstrate novel interactions of the cytoplasmic tail of PC1 with the 
mitochondrial proteins AIF and ATP synthase β-subunit along with the protein 
kinase mTOR. p30 is also involved in an anti-apoptotic mechanism in response to 
calcium-induced toxicity (Chapter III). Finally, I showed that a ketogenic diet can 
reduce cyst formation in a rodent model PKD and may be able to serve as a 
possible therapeutic for human ADPKD (Chapter IV).  
Each of these stories open fascinating new lines of investigation, and at the 
intersection of these separate projects lie powerful insights into the mechanisms of 
cystic disease progression, initiation and maintenance.  
Signaling Mechanisms in ADPKD; Reactive Oxygen Species 
Having demonstrated that crystals are capable of triggering cystogenesis, the 
next areas of research will need to elucidate the signaling mechanism underlying 
the transformation to a cyst. Amongst the most likely potential candidates for the 
upstream regulators of cyst formation are reactive oxygen species (ROS). Previous 
research has demonstrated that crystals activate the NAPDH oxidase enzyme in 
Madin-Darby Canine Kidney (MDCK) epithelial cells135. This increase of ROS 
has several implications in downstream effectors. Of potential interest is the 
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transcription factor hypoxia inducing factor 1-alpha (HIF1α). HIF1α is regulated 
by ubiquitin mediated protein degradation wherein ubiquitin attachment occurs by 
modification of proline residues that are hydroxylated in the presence of oxygen. 
The use of prolyl hydroxylase for the degradation of cellular proteins is also 
necessary for  polycystin-1 protein regulation114.  
It is interesting to note that ischemia reperfusion is capable of upregulating 
HIF1α136 and promoting cystogenesis in a Pkd-hypomorphic model of ADPKD3. 
HIF1α is seen upregulated in the Han:SPRD rat137 with the increase of mTOR 
signaling implicated at increasing the levels of HIF1α. Inhibition of HIF1α 
following ischemia reperfusion has been shown to prevent the accumulation of 
fibrotic tissue in the kidney136. However, inhibition of HIF1α was not sufficient to 
prevent cystic disease progression in the Han:SPRD model of PKD137. This could 
be due to the overactive mTOR activity already observed in the Han model. The 
activity of PI3K and mTOR is sufficient to increase levels of HIF1α even under 
normoxic conditions138. It is worth noting that the ketogenic diet upregulates 
HIF1α but simultaneously inhibits mTOR activation which may account for why 
there was still a positive effect in the Han rat.  
Fibrosis induced following ischemia may be mitigated by regulating 
overactive mTOR signaling. The use of the rapalog sirolimus, has been shown to 
be effective in ameliorating cystic disease in the Han rat139. Sirolimus affects both 
the mTORC1 and mTORC2 complexes, which would influence other pathways 
including autophagy and regulation of cell size, making it difficult to say what the 
effect is from. Other studies have shown that rapamycin and inhibitors that effect 
S6K can also prevent interstitial fibrosis and cystic disease progression140. This 
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places mTOR signaling upstream of the development of cystic kidney disease and 
has been demonstrated by several labs with the use of rapalogs and various models 
of PKD7,33,139.  
The use of ROS scavengers in PKD has been shown to be insufficient in 
preventing PKD in the Lewis polycystic kidney (LPK) rat141. The LPK model is an 
ARPKD model with effects in the primary cilium. Therefore, it may not be the 
best example of regulation of ROS in ADPKD.  
Additional support for the role of ROS in PKD is the use of angiotensinogen 
inhibitors as a treatment in animal models of PKD142. Angiotensin signaling 
produces ROS through intracellular NADPH oxidase143, similar to oxalate 
crystals. It may be that the role of PC1 in the injury response and the progression 
of PKD is its ability for oxygen sensation. This is exemplified by the ability of 
microcrystals to exacerbate PKD in the Han rat. Microcrystals produce ROS 
through the NADPH oxidase system, leading to the activation of the 
inflammasome and IL-1β secretion. The inflammatory response produced in this 
circumstance should be acute as the crystals are cleared out of the tubule lumen 
and away from activating ROS in cells. mTOR may be responsible for regulating 
this response under normal conditions and its overactivation leads to a runaway 
production of inflammatory cytokines and proliferation following injury.  
The inhibition of mTOR signaling may in fact be the inhibition of the 
production of inflammatory mediators in response to injury. The production of IL-
1β is a known mediator of inflammation, activating the innate immune response 
and a host of genes related to cell survival.  
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This becomes an interesting topic as the interplay between STAT signaling, 
mTOR, ROS and cystic kidney disease converge. We know that ischemic injury to 
the kidney leads to the production of ROS; this in turn increases the levels of 
HIF1α and p30. ROS is also capable of activating the caspase-1 inflammasome 
leading to the production of IL-1β. IL-1β in turn activates even more ROS 
production in neighboring cells leading to increased inflammation. The production 
of IL-1β can be mediated by the mTORC1 complex, reducing the effect of 
inflammation. p30 increases along with the increase in ROS due to the hypoxic 
conditions of the cell. This in turn sensitizes cells to the effects of STAT3 
signaling to initiate repair and proliferative responses. The C-terminal tail of PC1 
contains a caspase-1 cleavage site which creates a small bioactive fragment that is 
still capable of coactivating STAT3 gene activity. The function of this cleavage 
may be to interfere with p30 interaction with other key regulatory molecules or to 
create new interactions that p30 can regulate under inflammatory conditions. In 
cystic kidney disease, the regulation of these critical pathways by PC1 is no longer 
functioning. How this is occurring precisely is still under debate.  
p30 and Apoptosis 
After observing that p30 influences the survival of cells following calcium 
induced toxicity (Chapter III), it would be interesting to investigate this protective 
phenotype further. The role of PC1/PC2 as a calcium ion channel that interacts 
with a calcium sensitive protein like AIF along with PC1/PC2 regulating 
mitochondrial calcium levels under normoxic conditions opens exciting areas of 
exploration. It would also be interesting to understand if the interaction of the 
ATP synthase β-subunit is also involved in this mechanism of regulation. It is 
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intriguing to speculate that PC1 is involved in the regulation of oxidative 
phosphorylation at the level of both complex one and ATP synthase by either 
sequestration of critical subunits or by effecting their trafficking to the 
mitochondria. The low abundance of ATPase associated with p30 may be because 
the right conditions have not been replicated to increase or stabilize binding. 
Replicating the experiment under hypoxic conditions utilizing the full length PC1 
would be a great starting place. As of now, only the p30 fragment has been looked 
at for interacting with both AIF and the ATP synthase β-subunit. It would be 
interesting to test the ability of full length PC1 to bind to each of these proteins 
under both normoxia and hypoxia to see if they are differentially bound.  
Future Directions 
Future work on microcrystals would be to test the effect of stone preventative 
strategies for the treatment of PKD. Tanner et al showed that dietary citrate was 
able to improve the cystic phenotype in the Han rat66. Dietary intervention 
utilizing potassium citrate would act as a chelator of excess calcium, preventing 
the formation of any calcium dependent crystal. Reducing consumption of foods 
with large quantities of crystal forming agents (e.g. oxalate, phosphate, uric acid, 
calcium) could also be helpful in preventing disease progression. It would then 
make sense that PKD animals would exhibit increased markers of crystal 
precursors. Paradoxically, investigation into two mouse models of  ADPKD 
showed no changes in lithogenic parameters104. This observation may be 
explained by the fact that mice are notoriously poor crystal formers, making them 
the wrong models to study this effect. There is, however, an increased incidence of 
crystal formation in ADPKD human patients and an increase in lithogenic 
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parameters53,54. It is therefore worth it to study the effects of crystal inhibition in a 
suitable model of PKD.  
One of the problems with studying microcrystal induced PKD is the lack of an 
animal model orthologous to human ADPKD. The use of mice in genetic 
engineering has taken over the PKD field as the only models of PKD in rats have 
been discovered by random. It would therefore be prudent to produce an 
orthologous ADPKD rat model to study the effects of crystals on the progression 
of PKD. Creation of an inducible rat model of ADPKD would be a significant step 
in understanding the signaling of polycystin-1 following crystal deposition and 
allow for suitable tests to be done into the exploration of crystal induced PKD. 
ROS appear to be center stage in PKD and in the interaction of crystals with 
the kidney. To test the effect of ROS and crystals on PKD, pretreatment with an 
ROS scavenger followed by increases in crystal forming agents should be able to 
prevent an increase in cystogenesis. Research into the effect of ROS in PKD has 
showed that depletion of glutathione can increase the amount of cystogenesis in 
the Han rat144 and sodium thiosulfate has been shown to inhibit ethylene glycol 
induced hyperoxaluric renal damage by reducing oxidative stress in Wistar rats145. 
The link between kidney injury via ROS and the progression of PKD are 
unmistakable. It does appear that there may not be one singular cause of the 
generation of ROS that leads to PKD. Instead it appears that a combinatorial effect 
in the reduction of oxygen and the regulation of PC1 are explicably tied together 
in the pathogenesis of ADPKD. This decrease of oxygen can come from cellular 
signaling, increased aerobic metabolism or hypoxia. All of which cause the 
generation of ROS and a subsequent signaling cascade involving PC1.  
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Furthering the research into the effects of the ketogenic diet on PKD would be 
test the effect of the primary ketone body β-hydroxybutyrate (βHB). βHB can be 
supplemented as a powder that can be administered in the drinking water or in the 
feed. If the effects of the ketotic state are in fact a product of βHB signaling, then 
the supplementation of the βHB salt should be sufficient in protecting animals 
from disease progression. 
To counteract the decreased weight gain seen in rats from a strict ketogenic 
diet may be to use a cyclical ketogenic approach. This type of ketogenic diet 
approach has been used because of increased sensitivity of insulin, growth 
hormone and mTOR signaling. This approach would allow for periodic “refeeds” 
in which animals eat more carbohydrates and protein before returning to a strict 
ketogenic diet. Modification of the dietary protein may also allow for the benefits 
of ketosis without the decreased weight gain.  
 Furthering the experiment, I presented here on the effect of ketosis in PKD 
would need to be repeated with an orthologous model of PKD, one that has a 
mutation in polycystin-1/2. This experiment is currently possible as mice are 
suitable to treat with a ketogenic diet.   
Conclusion 
During the tenure of my time as a graduate researcher, I investigated the 
mechanisms of PKD, beginning with studying the small soluble tail of PC1 
followed by research into the possible endogenous injury mechanism for cyst 
formation. The search for the endogenous “third hit” in ADPKD led to the 
discovery of a yet unrecognized mTOR dependent mechanism that facilitates the 
removal of crystals in the kidney. The injury caused by microcrystals was shown 
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to be conserved amongst mice, rats and humans. With the discovery that 
microcrystals may exacerbate PKD, new therapeutic approaches can be 
investigated that target the initiation of cysts rather than trying to halt the 
progression of formed cysts.  
The results obtained from the experiments with ethylene glycol treated rats 
showed that microcrystals can exacerbate the rate of cyst development. This was 
done in a sex specific manner, with males being affected over females. Crystal 
deposition appears necessary for cystogenesis as cystic females appeared 
unaffected and did not show crystal deposition. This finding shows that there is a 
possibility for therapeutic intervention utilizing dietary citrate as a calcium 
chelator and alkalinizing agent alongside other dietary recommendations to reduce 
and eliminate stone forming agents in the urinary filtrate. By increasing the intake 
of water, alkalinizing foods and compounds such as sodium bicarbonate along 
with removing foods with high levels of oxalate or protein may all be effective 
strategies to reduce the crystal burden in the kidneys. If the disease progression 
can be lengthened and the rate of cystogenesis can be modified so that the quality 
of life can be extended, it will effectively act as a cure for the disease until a time 
as a more specific therapy can be discovered. The biggest obstacle to the treatment 
of ADPKD is the systematic loss of healthy tissue due to the progression of cyst 
formation. Intervention that occurs early in life would able to preserve kidney 
function and circumvent the need for dialysis and transplant later in life. 
Along with the finding that crystals exacerbate PKD, I demonstrated that a 
ketogenic diet may also be an effective intervention for the treatment of PKD. 
Both the dietary intervention to prevent stones and the ketogenic diet share 
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similarities in that they are aimed at reducing inflammation and the production of 
dangerous free radicals. If future research continues to remain positive, these 
treatments may one day be clinical approaches for the treatment of ADPKD. 
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VII. Appendix
 
Supplemental Figure 1: Ki-67 stained kidneys of rapamycin treated and 
control rats: Wild-type Sprague Dawley rats were pretreated with rapamycin 
before IP injection of sodium oxalate. Animals were assessed for Ki-67 up to 7 
days post treatment.  
 
 
 
Supplemental Table 1: Animal measurements for high phosphate diet pck rats: 
Male and female pck rats treated on either a high phosphate (1.2%) or normal 
phosphate (0.6%) diet were evaluated for markers of kidney performance.  
